Exhibit 10.2

 

CERTAIN MATERIAL (INDICATED BY [***]) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT.  THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

PLEDGE AND SECURITY AGREEMENT

 

THIS PLEDGE AND SECURITY AGREEMENT, dated as of the 2nd day of April, 2015 (this “Agreement”), is made by DEPOMED, INC., a California corporation (the “Borrower”), by DEPO NF SUB, LLC, a Delaware limited liability company and a Subsidiary of the Borrower (“Acquisition Subsidiary”), and by each Subsidiary of the Borrower that, after the date hereof, executes an instrument of accession hereto substantially in the form of Exhibit C (a “Pledgor Accession”; such Subsidiaries, collectively, together with the Borrower and the Acquisition Subsidiary, the “Pledgors”), in favor of DEERFIELD PRIVATE DESIGN FUND III, L.P., a Delaware limited partnership, as Collateral Agent for the Purchasers party to the Note Purchase Agreement referred to below (in such capacity, the “Collateral Agent”), for the benefit of the Secured Parties (as hereinafter defined).  Except as otherwise provided herein, capitalized terms used but not defined herein have the meanings given to them in the Note Purchase Agreement referred to below.

 

RECITALS

 

A.                                    The Borrower, the Purchasers and the Collateral Agent are parties to a Note Purchase Agreement, dated as of March 12, 2015 (as amended, modified, restated or supplemented from time to time, the “Note Purchase Agreement”), pursuant to which the Purchasers will purchase Notes with an aggregate original principal amount of $575,000,000 upon the terms and subject to the conditions set forth therein.

 

B.                                    As a condition to the purchase of the Notes by the Purchasers under the Note Purchase Agreement, the Acquisition Subsidiary has entered into a Guaranty Agreement, dated as of the date hereof (as amended, modified, restated or supplemented from time to time, the “Guaranty Agreement”), pursuant to which the Acquisition Subsidiary has guaranteed to the Secured Parties the payment in full of the Obligations of the Borrower under the Note Purchase Agreement and the other Credit Documents.  Additionally, certain other Subsidiaries of the Borrower may from time to time after the date hereof enter into the Guaranty Agreement, pursuant to which such Subsidiaries will guarantee to the Secured Parties the payment in full of the Obligations of the Borrower under the Note Purchase Agreement and the other Credit Documents.

 

C.                                    It is a further condition to the purchase by the Purchasers of the Notes under the Note Purchase Agreement that the Pledgors as of the date of the Note Purchase Agreement shall have agreed, by executing and delivering this Agreement, to secure the payment in full of their respective obligations under the Note Purchase Agreement, the Guaranty Agreement and the other Credit Documents.  The Secured Parties are relying on this Agreement in their decision to purchase the Notes from the Borrower under the Note Purchase Agreement, and would not enter

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 











 

into the Note Purchase Agreement or purchase the Note thereunder without the execution and delivery of this Agreement by the Pledgors.

 

D.                                    The Pledgors will obtain benefits as a result of the sale by the Borrower of the Notes to the Purchasers under the Note Purchase Agreement, which benefits are hereby acknowledged, and, accordingly, desire to execute and deliver this Agreement.

 

STATEMENT OF AGREEMENT

 

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, to induce the Secured Parties to enter into the Note Purchase Agreement and to induce the Purchasers to purchase the Notes from the Borrower thereunder, each Pledgor hereby agrees as follows:

 

ARTICLE I

 

DEFINITIONS

 

1.1                               Defined Terms.  The following terms that are defined in the Uniform Commercial Code (as hereinafter defined) are used in this Agreement as so defined (and, in the event any such term is defined differently for purposes of Article 9 of the Uniform Commercial Code than for any other purpose or purposes of the Uniform Commercial Code, the Article 9 definition shall govern): Account, Chattel Paper, Commercial Tort Claim, Commodity Account, Commodity Intermediary, Deposit Accounts, Documents, Electronic Chattel Paper, Equipment, Fixtures, General Intangibles, Goods, Instruments, Inventory, Investment Property, Letter-of-Credit Rights, Record, Securities Account, Securities Intermediary, Software, Supporting Obligations and Tangible Chattel Paper.  In addition, the following terms have the meanings set forth below:

 

“Collateral” has the meaning given to such term in Section 2.1.

 

“Collateral Accounts” has the meaning given to such term in Section 6.3.

 

“Contracts” means, collectively, all rights of each Pledgor under all leases, contracts and agreements to which such Pledgor is now or hereafter a party, including, without limitation, all rights, privileges and powers under Ownership Agreements and Licenses, together with any and all extensions, modifications, amendments and renewals of such leases, contracts and agreements and all rights of such Pledgor to receive moneys due or to become due thereunder or pursuant thereto and to amend, modify, terminate or exercise rights under such leases, contracts and agreements.

 

“Control Agreement” has the meaning given to such term in Section 4.7.

 

“Copyright Collateral” means, collectively, all Copyrights and inbound Copyright Licenses (other than off-the-shelf software and software subject to shrink-wrap, click-wrap and other generally commercially available licenses) to which any Pledgor is or hereafter becomes a party and all other General Intangibles embodying, incorporating, evidencing or otherwise

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

2











 

relating or pertaining to any Copyright or Copyright License, in each case whether now owned or existing or hereafter acquired or arising.

 

“Copyright License” means any agreement now or hereafter in effect granting any right to any third party under any Copyright now or hereafter owned by any Pledgor or which any Pledgor otherwise has the right to license, or granting any right to any Pledgor under any property of the type described in the definition of Copyright herein now or hereafter owned by any third party, and all rights of any Pledgor under any such agreement.

 

“Copyrights” means, collectively, all of each Pledgor’s copyrights, copyright registrations and applications for copyright registration, whether under the laws of the United States or any other country or jurisdiction, including all recordings, supplemental registrations and derivative or collective work registrations, and all renewals and extensions thereof, in each case whether now owned or existing or hereafter acquired or arising.

 

“Excluded Property” means collectively, (i) any permit, license or agreement entered into by any Pledgor (A) to the extent that any such permit, license or agreement or any law applicable thereto prohibits the creation of a Lien thereon, but only to the extent, and for as long as, such prohibition is not terminated or rendered unenforceable or otherwise deemed ineffective by the Uniform Commercial Code or any other applicable law or (B) to the extent that the creation of a Lien in favor of the Collateral Agent would result in a breach or termination pursuant to the terms of or a default under any such permit, license or agreement (other than to the extent that any such term would be rendered ineffective pursuant to the Sections 9-406, 9-407, 9-408 or 9-409 of the Uniform Commercial Code or any other applicable law (including the Bankruptcy Code) or principles of equity), (ii) property owned by any Pledgor that is subject to a purchase money Lien or leased by any Pledgor that is subject to a Capital Lease, in each case, permitted under the Note Purchase Agreement if the agreement pursuant to which such Lien is granted (or in the document providing for such capital lease) (1) prohibits or requires the consent of any Person other than a Pledgor or one of its Affiliates which has not been obtained as a condition to the creation of any other Lien on such property or (2) grants a right of termination to any Person other than a Pledgor or one of its Affiliates if any Lien in favor of the Collateral Agent is created with respect to the property subject thereto, (iii) any “intent to use” trademark applications for which a statement of use has not been filed (but only until such statement is filed), (iv) Capital Stock in joint ventures or any non-Wholly Owned Subsidiaries to the extent not permitted by the terms of such entity’s organizational documents or joint venture documents, (v) voting Capital Stock in any Excluded Foreign Subsidiary in excess of 65% of the total combined voting power of all outstanding classes of Capital Stock in such Subsidiary (within the meaning of Section 1.956-2(c)(2) of the Treasury Regulations), (vi) rolling stock, motor vehicles, vessels and other assets subject to certificates of title (other than to the extent a Lien thereon can be perfected by the filing of a financing statement under the Uniform Commercial Code), (vii) any governmental licenses or state or local franchises, charters and authorizations, to the extent a security interest in any such license, franchise, charter or authorization is prohibited or restricted thereby (after giving effect to the applicable anti-assignment provisions of the Uniform Commercial Code or other applicable law), (viii) any assets (including intangibles) not located in the United States to the extent the grant of a security interest therein is restricted or prohibited by applicable law, and (ix) [***]; provided, however, “Excluded Property” shall not include any proceeds, products, substitutions or replacements of

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

3











 

Excluded Property (unless such proceeds, products, substitutions or replacements would otherwise constitute Excluded Property).

 

“Excluded Securities Account” means (i) any Securities Account or Commodity Account where the aggregate value of the securities or commodities credited thereto does not at any time exceed [***] for such account or [***] for all such accounts, (ii) any Securities Account or Commodity Account where (A) the Collateral Agent is the entitlement holder or Commodity Intermediary or (B) the Securities Intermediary or Commodity Intermediary (as applicable) for such account has executed and delivered to the Collateral Agent a control agreement with respect to such Securities Account or Commodity Account in form and substance reasonably satisfactory to the Collateral Agent, (iii) any Securities Account or Commodity Account described in clause (ii) of the definition of Excluded Account, and (iv) any Securities Account or Commodity Account held outside the United States.

 

“Guarantor” has the meaning given such term in the Guaranty Agreement.

 

“License” means any Copyright License, Patent License or Trademark License.

 

“Ownership Agreement” means any partnership agreement, joint venture agreement, limited liability company operating agreement, stockholders agreement or other agreement creating, governing or evidencing any Capital Stock and to which any Pledgor is now or hereafter becomes a party, as any such agreement may be amended, modified, supplemented, restated or replaced from time to time.

 

“Patent Collateral” means, collectively, all Patents and all inbound Patent Licenses to which any Pledgor is or hereafter becomes a party and all other General Intangibles embodying, incorporating, evidencing or otherwise relating or pertaining to any Patent or Patent License, in each case whether now owned or existing or hereafter acquired or arising.

 

“Patent License” means any agreement now or hereafter in effect granting to any third party any right to make, use or sell any invention on which a Patent, now or hereafter owned by any Pledgor or which any Pledgor otherwise has the right to license, is in existence, or granting to any Pledgor any right to make, use or sell any invention on which property of the type described in the definition of Patent herein, now or hereafter owned by any third party, is in existence, and all rights of any Pledgor under any such agreement.

 

“Patents” means, collectively, all of each Pledgor’s letters patent, whether under the laws of the United States or any other country or jurisdiction, all recordings and registrations thereof and applications therefor, including, without limitation, the inventions and improvements described therein, and all reissues, continuations, divisions, renewals, extensions, substitutions and continuations-in-part thereof, in each case whether now owned or existing or hereafter acquired or arising.

 

“Pledge Amendment” has the meaning given such term in Section 5.1(a).

 

“Pledged Interests” means, collectively, (i) all of the issued and outstanding Capital Stock of each Person that is a direct Subsidiary of any Pledgor as of the date hereof or that becomes a direct Subsidiary of any Pledgor at any time after the date hereof, at any time now or hereafter

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

4











 

owned by any Pledgor, whether voting or non-voting and whether common or preferred; (ii) all options, warrants and other rights to acquire, and all securities convertible into, any of the foregoing; (iii) all rights to receive interest, income, dividends, distributions, returns of capital and other amounts (whether in cash, securities, property, or a combination thereof), and all additional stock, warrants, options, securities, interests and other property, from time to time paid or payable or distributed or distributable in respect of any of the foregoing (but subject to the provisions of Section 5.3), including, without limitation, all rights of such Pledgor to receive amounts due and to become due under or in respect of any Ownership Agreement or upon the termination thereof; (iv) all rights of access to the books and records of any such Person (other than with respect to the books and records held by Depo DR); and (v) all other rights, powers, privileges, interests, claims and other property in any manner arising out of or relating to any of the foregoing, of whatever kind or character (including any tangible or intangible property or interests therein), and whether provided by contract or granted or available under applicable law in connection therewith, including, without limitation, such Person’s right to vote and to manage and administer the business of any such Subsidiary pursuant to any applicable Ownership Agreement, in each case together with all certificates, instruments and entries upon the books of financial intermediaries at any time evidencing any of the foregoing.  Notwithstanding the foregoing, Pledged Interests shall not include any Excluded Property specified in clause (v) of the definition thereof.

 

“Proceeds” has the meaning given to such term in Section 2.1.

 

“Secured Parties” means, collectively, the Purchasers and the Collateral Agent.

 

“Secured Obligations” has the meaning given such term in Section 2.2.

 

“Trademark Collateral” means, collectively, all Trademarks and inbound Trademark Licenses to which any Pledgor is or hereafter becomes a party and all other General Intangibles embodying, incorporating, evidencing or otherwise relating or pertaining to any Trademark or Trademark License, in each case whether now owned or existing or hereafter acquired or arising.

 

“Trademark License” means any agreement now or hereafter in effect granting any right to any third party under any Trademark now or hereafter owned by any Pledgor or which any Pledgor otherwise has the right to license, or granting any right to any Pledgor under any property of the type described in the definition of Trademark herein now or hereafter owned by any third party, and all rights of any Pledgor under any such agreement.

 

“Trademarks” means, collectively, all of each Pledgor’s trademarks, service marks, trade names, corporate and company names, business names, logos, trade dress, trade styles, other source or business identifiers, designs and general intangibles of a similar nature, whether under the laws of the United States or any other country or jurisdiction, all recordings and registrations thereof and applications therefor, all renewals, reissues and extensions thereof, all rights corresponding thereto, and all goodwill associated therewith or symbolized thereby, in each case whether now owned or existing or hereafter acquired or arising.

 

“Uniform Commercial Code” means the Uniform Commercial Code as the same may be in effect from time to time in the State of New York; provided that if, by reason of applicable law, the validity, priority or perfection of any security interest in any Collateral granted under

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

5











 

this Agreement is governed by the Uniform Commercial Code as in effect in another jurisdiction, then as to the validity, priority or perfection, as the case may be, of such security interest, “Uniform Commercial Code” means the Uniform Commercial Code as in effect from time to time in such other jurisdiction.

 

1.2                               Other Terms; Construction.  All terms in this Agreement that are not capitalized shall, unless the context otherwise requires, have the meanings provided by the Uniform Commercial Code to the extent the same are used or defined therein.

 

ARTICLE II

 

CREATION OF SECURITY INTEREST

 

2.1                               Pledge and Grant of Security Interest.  Each Pledgor hereby pledges and collaterally assigns to the Collateral Agent, for the ratable benefit of the Secured Parties, and grants to the Collateral Agent, for the ratable benefit of the Secured Parties, a Lien upon and security interest in, all of such Pledgor’s right, title and interest in and to the following property and assets of such Pledgor, in each case whether now owned or existing or hereafter acquired or arising and wherever located (collectively, the “Collateral”):

 

(i)                                     all Accounts;

 

(ii)                                  all Chattel Paper;

 

(iii)                               the Commercial Tort Claims (if any) set forth on Annex I hereto;

 

(iv)                              all Contracts;

 

(v)                                 all Copyright Collateral;

 

(vi)                              all Deposit Accounts;

 

(vii)                           all Documents;

 

(viii)                        all Equipment;

 

(ix)                              all Fixtures;

 

(x)                                 all General Intangibles;

 

(xi)                              all Goods;

 

(xii)                           all Instruments;

 

(xiii)                        all Inventory;

 

(xiv)                       all Investment Property;

 

(xv)                          all Letter-of-Credit Rights;

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

6











 

(xvi)                       all Patent Collateral;

 

(xvii)                    all Pledged Interests;

 

(xviii)                 all Software;

 

(xix)                       all Supporting Obligations;

 

(xx)                          all Trademark Collateral;

 

(xxi)                       all cash, cash equivalents and money of such Pledgor, wherever held;

 

(xxii)                    to the extent not covered or not specifically excluded by clauses (i) through (xxi) above, all of such Pledgor’s other personal property;

 

(xxiii)                 all Records evidencing or relating to any of the foregoing or that are otherwise necessary or useful in the collection thereof;

 

(xxiv)                all accessions, additions, attachments, improvements, modifications and upgrades to, replacements of and substitutions for any of the foregoing; and

 

(xxv)                   any and all proceeds, as defined in the Uniform Commercial Code, products, rents, royalties and profits of or from any and all of the foregoing and, to the extent not otherwise included in the foregoing, (w) all payments under any insurance (whether or not the Collateral Agent is the loss payee thereunder), indemnity, warranty or guaranty with respect to any of the foregoing Collateral, (x) all payments in connection with any requisition, condemnation, seizure or forfeiture with respect to any of the foregoing Collateral, (y) all claims and rights (but not obligations) to recover for any past, present or future infringement or dilution of or injury to any Copyright Collateral, Patent Collateral or Trademark Collateral, and (z) all other amounts from time to time paid or payable under or with respect to any of the foregoing Collateral (collectively, “Proceeds”).  For purposes of this Agreement, the term “Proceeds” includes whatever is receivable or received when Collateral or Proceeds are sold, exchanged, collected or otherwise disposed of, whether voluntarily or involuntarily.

 

Notwithstanding the foregoing, (i) “Collateral” shall not include the Excluded Property, and (ii) the Collateral Agent may, in its sole discretion, reject or refuse to accept for credit toward payment of the Secured Obligations any Collateral that is an Account, Instrument, Chattel Paper, lease or other obligation or property of any kind due or owing from or belonging to a Sanctioned Person.

 

2.2                               Security for Secured Obligations.  This Agreement and the Collateral secure the full and prompt payment, at any time and from time to time as and when due (whether at the stated maturity, by acceleration or otherwise), of (a) in the case of the Borrower, all Obligations of the Borrower under the Note Purchase Agreement and the other Credit Documents, including, without limitation, all principal of and interest on the Notes, and all fees, expenses, indemnities and other amounts payable by the Borrower under the Note Purchase Agreement or any other Credit Document (including interest accruing after the filing of a petition or commencement of a

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

7











 

case by or with respect to the Borrower seeking relief under any applicable federal and state laws pertaining to bankruptcy, reorganization, arrangement, moratorium, readjustment of debts, dissolution, liquidation or other debtor relief, specifically including, without limitation, the Bankruptcy Code and any fraudulent transfer and fraudulent conveyance laws, whether or not the claim for such interest is allowed in such proceeding), and (b) in the case of each Pledgor other than the Borrower, if any, all of its liabilities and obligations as a Guarantor in respect of the Guaranteed Obligations (as defined in the Guaranty Agreement); and in each case under (a) and (b) above, (i) all such liabilities and obligations that, but for the operation of the automatic stay under Section 362(a) of the Bankruptcy Code, would become due, and (ii) all fees, costs and expenses payable by the Pledgors under Section 8.1, whether now existing or hereafter created or arising and whether direct or indirect, absolute or contingent, due or to become due (the liabilities and obligations of the Pledgors described in this Section 2.2, collectively, the “Secured Obligations”).

 

ARTICLE III

 

REPRESENTATIONS AND WARRANTIES

 

Each Pledgor represents and warrants as follows:

 

3.1                               Ownership of Collateral.  Each Pledgor (i) holds interests as lessee under valid leases in full force and effect with respect to all material leased real and personal property used in connection with its business and (ii) has good title to all of its other material properties and assets reflected in the financial statements referred to in Section 4.9 of the Note Purchase Agreement (except as sold or otherwise disposed of since the date thereof in the ordinary course of business), in each case free and clear of all Liens other than Permitted Liens.  No security agreement, financing statement or other public notice with respect to all or any part of the Collateral is on file or of record in any government or public office, and no Pledgor has filed or consented to the filing of any such statement or notice, except (i) Uniform Commercial Code financing statements naming the Collateral Agent as secured party, (ii) security instruments filed in the U.S. Copyright Office or the U.S. Patent and Trademark Office naming the Collateral Agent as secured party, (iii) filings with respect to which termination statements and other necessary releases have been delivered to the Collateral Agent for filing or will be filed promptly on or after the date hereof (or the date of the applicable Pledgor Accession), (iv) Uniform Commercial Code financing statements and security instruments filed in the U.S. Copyright Office or the U.S. Patent and Trademark Office [***], and (v) as may be otherwise permitted by the Note Purchase Agreement.

 

3.2                               Security Interests; Filings.  This Agreement, together with (i) the filing, with respect to each Pledgor, of duly completed Uniform Commercial Code financing statements naming such Pledgor as debtor, the Collateral Agent as secured party, and describing the Collateral, in the jurisdictions set forth with respect to such Pledgor on Annex A hereto, (ii) to the extent required by applicable law, the filing, with respect to each relevant Pledgor, of duly completed and executed assignments in the forms set forth as Exhibits A and B with the U.S. Copyright Office or the U.S. Patent and Trademark Office, as appropriate, with regard to registered Copyright Collateral, Patent Collateral and Trademark Collateral of such Pledgor, as the case may be, (iii) in the case of uncertificated Pledged Interests consisting of capital stock, registration of transfer thereof to the Collateral Agent on the issuer’s books or the execution by

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

8











 

the issuer of a control agreement satisfying the requirements of Section 8-106 (or its successor provision) of the Uniform Commercial Code, and (iv) the delivery to the Collateral Agent, for its benefit and the benefit of the Secured Parties, of all stock certificates and Instruments included in the Collateral (and assuming continued possession thereof by the Collateral Agent), creates, and at all times shall constitute, a valid and perfected security interest in and Lien upon the Collateral in favor of the Collateral Agent, for the benefit of the Secured Parties, to the extent a security interest therein can be perfected by such filings or possession, as applicable, superior and prior to the rights of all other Persons therein (except for Permitted Liens), and no other or additional filings, registrations, recordings or actions are or shall be necessary or appropriate in order to maintain the perfection and priority of such Lien and security interest, other than actions required with respect to Collateral of the types excluded from Article 9 of the Uniform Commercial Code or from the filing requirements under such Article 9 by reason of Section 9 109, 9-309 or 9 310 of the Uniform Commercial Code and other than continuation statements required under the Uniform Commercial Code.

 

3.3                               Locations.  Annex B lists, as to each Pledgor, (i) its exact legal name, (ii) the jurisdiction of its incorporation or organization, its federal tax identification number, and (if applicable) its organizational identification number, (iii) the addresses of its chief executive office and each other place of business, (iv) the address of each location of all original invoices, ledgers, Chattel Paper, Instruments and other records or information evidencing or relating to the Collateral of such Pledgor, and (v) the address of each location at which any Equipment or Inventory (other than Goods in transit and mobile goods) having a book value in excess of [***] and owned by such Pledgor is kept or maintained, in each instance except for any new locations established in accordance with the provisions of Section 4.1.  Except as may be otherwise noted therein, all locations identified in Annex B are leased by the applicable Pledgor. No Pledgor (x) presently conducts or has conducted business under any prior or other corporate or company name or under any trade or fictitious names, except as indicated beneath its name on Annex B or (y) has filed any tax return under any name other than its exact legal name, except as indicated beneath its name on Annex B.

 

3.4                               Authorization; Consent.  No authorization, consent or approval of, or declaration or filing with, any Governmental Authority (including, without limitation, any notice filing with state tax or revenue authorities required to be made by account creditors in order to enforce any Accounts in such state) is required for the valid execution, delivery and performance by any Pledgor of this Agreement, the grant by it of the Lien and security interest in favor of the Collateral Agent provided for herein, or the exercise by the Collateral Agent of its rights and remedies hereunder, except for (i) the filings described in Section 3.2, (ii) in the case of Accounts owing from any federal governmental agency or authority, the filing by the Collateral Agent of a notice of assignment in accordance with the federal Assignment of Claims Act of 1940, as amended, (iii) in the case of Pledged Interests, such filings and approvals as may be required in connection with a disposition of any such Pledged Interests by laws affecting the offering and sale of securities generally, (iv) authorizations, consents, approvals, declarations or filings relating to the possession and sale or other disposition of any controlled substances, and (v) authorizations, consents, approvals, declarations or filings relating to the transfer or assignment of any Collateral constituting Regulatory Approvals.

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

9











 

3.5                               No Restrictions.  There are no statutory or regulatory restrictions, prohibitions or limitations on any Pledgor’s ability to grant to the Collateral Agent a Lien upon and security interest in the Collateral pursuant to this Agreement or (except for (i) the provisions of the federal Anti-Assignment Act, as amended, and Assignment of Claims Act of 1940, as amended, (ii) any statutory or regulatory restrictions, prohibitions or limitations relating to the possession and sale or other disposition of any controlled substances and (iii) any statutory or regulatory restrictions, prohibitions or limitations applicable to the transfer of any Collateral constituting Regulatory Approvals) on the exercise by the Collateral Agent of its rights and remedies hereunder (including any foreclosure upon or collection of the Collateral), and there are no contractual restrictions on any Pledgor’s ability to grant such Lien and security interest.

 

3.6                               Accounts.  Each Account is, or at the time it arises will be not evidenced by any Tangible Chattel Paper or other Instrument; or if so, such Tangible Chattel Paper or other Instrument valued individually in excess of [***] or [***] in the aggregate (other than invoices and related correspondence and supporting documentation) shall promptly be duly endorsed to the order of the Collateral Agent and delivered to the Collateral Agent to be held as Collateral hereunder.

 

3.7                               Pledged Interests.  As of the date hereof, the Pledged Interests required to be pledged hereunder by each Pledgor consist of the number and type of shares of capital stock (in the case of issuers that are corporations) or the percentage and type of other equity interests (in the case of issuers other than corporations) as described beneath such Pledgor’s name in Annex C.  All of the Pledged Interests (other than with respect to non-Wholly Owned Subsidiaries and joint ventures), and to such Pledgor’s knowledge, all of the Pledged Interests with respect to non-Wholly Owned Subsidiaries and joint ventures, have been duly and validly issued and are fully paid and nonassessable (or, in the case of partnership, limited liability company or similar Pledged Interests, not subject to any capital call or other additional capital requirement) and not subject to any preemptive rights, warrants, options or similar rights or restrictions in favor of third parties or any contractual or other restrictions upon transfer.  As to each issuer thereof, the Pledged Interests pledged hereunder constitute 100% or 65%, as applicable, of the outstanding Capital Stock of such issuer, except as set forth in Annex C.

 

3.8                               Intellectual Property.  Annexes D, E and F correctly set forth all registered Copyrights, Patents and Trademarks owned by any Pledgor as of the date hereof (and as amended from time to time pursuant to Section 4.5) and used or proposed to be used in its business.

 

3.9                               Deposit Accounts.  Annex G lists, as of the date hereof (and as amended from time to time pursuant to Section 4.7), all Deposit Accounts maintained by any Pledgor, and lists in each case the name in which the account is held, the name of the depository institution, the account number, and a description of the type or purpose of the account.

 

3.10                        Securities and Commodity Accounts.  Annex H lists, as of the date hereof (and as amended from time to time pursuant to Section 4.8), all Securities Accounts and Commodity Accounts maintained by any Pledgor with any Securities Intermediary or Commodity Intermediary, and lists in each case the name in which the account is held, the name of the Securities Intermediary or Commodity Intermediary, the account number, and a description of the type or purpose of the account.

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

10












 

3.11                        Documents of Title.  No bill of lading, warehouse receipt or other Document or Instrument of title is outstanding with respect to any Collateral other than Inventory in transit in the ordinary course of business to a location set forth on Annex B or to a customer of a Pledgor.

 

3.12                        Commercial Tort Claims.  Annex I lists, as of the date hereof and to the knowledge of each Pledgor, all Commercial Tort Claims valued individually in excess of [***] existing in favor of any Pledgor.

 

ARTICLE IV

 

COVENANTS

 

4.1                               Change of Name, Locations, etc.  No Pledgor will (i) change its name, identity or corporate structure, (ii) change its chief executive office from the location thereof listed on Annex B, (iii) change the jurisdiction of its incorporation or organization from the jurisdiction listed on Annex B (whether by merger or otherwise), (iv) file any document with the Internal Revenue Service using any name other than its exact legal name listed on Annex B, or (v)  remove any books, records or other information relating to the regulatory approvals, clinical studies or Intellectual Property related to a Material Product, from the applicable location thereof listed on Annex B, unless in each case such Pledgor has (1) given [***] (or such later date as may be agreed to by the Collateral Agent in its sole discretion) prior written notice to the Collateral Agent of its intention to do so, together with information regarding any such new location and such other information in connection with such proposed action as the Collateral Agent may reasonably request, and (2) delivered to the Collateral Agent [***] following the Collateral Agent’s request any documents, instruments or financing statements as may be reasonably required by the Collateral Agent, all in form and substance reasonably satisfactory to the Collateral Agent, paid all necessary filing and recording fees and taxes, and taken all other actions reasonably requested by the Collateral Agent, in order to perfect and maintain the Lien upon and security interest in the Collateral provided for herein in accordance with the provisions of Section 3.2.

 

4.2                               Reserved.

 

4.3                               Accounts.  Each Pledgor shall promptly notify the Collateral Agent in writing of any Accounts that constitute a claim valued individually in excess of [***] against a federal governmental agency or authority, and, upon request of the Collateral Agent, such Pledgor shall take such steps as may be necessary or desirable to comply with the federal Assignment of Claims Act of 1940, as amended.

 

4.4                               Delivery of Certain Collateral; Further Actions.  All (i) certificates or (ii) Instruments representing or evidencing any Accounts, Investment Property or other Collateral valued individually in excess of [***] or [***] in the aggregate shall be delivered promptly to the Collateral Agent pursuant hereto to be held as Collateral hereunder, shall be in form suitable for transfer by delivery and shall be delivered together with undated stock powers duly executed in blank, appropriate endorsements or other necessary instruments of registration, transfer or assignment, duly executed and in form and substance satisfactory to the Collateral Agent, and in each case together with such other instruments or documents as the Collateral Agent may reasonably request.  Each Pledgor will, at its own cost and expense, use commercially reasonable efforts to

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

11











 

cooperate with the Collateral Agent in obtaining a control agreement, in form and substance reasonably satisfactory to the Collateral Agent, and in taking such other actions as may be reasonably requested by the Collateral Agent from time to time with respect to any Investment Property or other Collateral in which a security interest may be perfected by (or can be perfected only by) control under the Uniform Commercial Code.

 

4.5                               Intellectual Property.

 

(a)                                 Each applicable Pledgor will, at its own expense, execute and deliver to the Collateral Agent on the Closing Date fully completed assignments in the forms of Exhibits A and B, as applicable, for recordation in the U.S. Copyright Office or the U.S. Patent and Trademark Office with regard to any Copyright Collateral, Patent Collateral or Trademark Collateral, as the case may be, described in Annex D, E or F hereto.  Within [***] after the close of each fiscal quarter of the Borrower, the Borrower shall provide written notice of any additional registrations of or applications for Copyrights, Patents or Trademarks of all Pledgors with the U.S. Copyright Office or the U.S. Patent and Trademark Office, as applicable, together with information sufficient to permit the Collateral Agent, upon its receipt of such notice, to (and each Pledgor hereby authorizes the Collateral Agent to) modify this Agreement, as appropriate, by amending Annexes D, E and F hereto or to add additional exhibits hereto to include any Copyright, Patent or Trademark that becomes part of the Collateral under this Agreement, and such Pledgor shall additionally, at its own expense, execute and deliver to the Collateral Agent, with regard to United States Patents, Trademarks and Copyrights, fully completed assignments in the forms of Exhibits A and B, as applicable, for recordation in the U.S. Copyright Office or the U.S. Patent and Trademark Office as more fully described hereinabove, together in all instances with any other agreements, instruments and documents that the Collateral Agent may reasonably request from time to time to further effect and confirm the assignment and security interest created by this Agreement in such Copyrights, Patents and Trademarks, and each Pledgor hereby appoints the Collateral Agent its attorney-in-fact to execute, deliver and record any and all such agreements, instruments and documents for the foregoing purposes, all acts of such attorney being hereby ratified and confirmed and such power, being coupled with an interest, shall be irrevocable for so long as this Agreement shall be in effect with respect to such Pledgor.

 

(b)                                 Upon the occurrence and during the continuance of any Event of Default, each Pledgor shall use commercially reasonable efforts to obtain all requisite consents or approvals from the licensor of each License included within the Copyright Collateral, Patent Collateral or Trademark Collateral to effect the assignment of all of such Pledgor’s right, title and interest thereunder to the Collateral Agent or its designee.

 

4.6                               Reserved.

 

4.7                               Deposit Accounts.  Subject to Section 5.13 of the Note Purchase Agreement, each Pledgor agrees that, unless the Collateral Agent consents otherwise in writing, (i) it will not open or maintain any Deposit Account (other than Excluded Accounts) except with a bank or financial institution that has executed and delivered to the Collateral Agent a control agreement with respect to such Deposit Account in form and substance reasonably satisfactory to the Collateral Agent (each a, “Control Agreement”), and (ii) in the event any Pledgor opens any Deposit Account not already listed on Annex G, such Pledgor shall (in addition to complying with the other requirements of this Section) promptly furnish written notice thereof to the Collateral

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

12











 

Agent together with information sufficient to permit the Collateral Agent, upon its receipt of such notice, to (and each Pledgor hereby authorizes the Collateral Agent to) modify this Agreement, as appropriate, by amending Annex G to include such information.

 

4.8                               Securities and Commodity Accounts.  Subject to Section 5.13 of the Note Purchase Agreement, each Pledgor agrees that, unless the Collateral Agent consents otherwise in writing, (i) it will not open or maintain any Securities Account or Commodity Account (other than Excluded Securities Accounts) unless the Collateral Agent is the entitlement holder or Commodity Intermediary or unless the Securities Intermediary or Commodity Intermediary (as applicable) has executed and delivered to the Collateral Agent a control agreement with respect to such Securities Account or Commodity Account in form and substance reasonably satisfactory to the Collateral Agent, and (ii) in the event any Pledgor opens any Securities Account or Commodity Account not already listed on Annex H, such Pledgor shall (in addition to complying with the other requirements of this Section) promptly furnish written notice thereof to the Collateral Agent together with information sufficient to permit the Collateral Agent, upon its receipt of such notice, to (and each Pledgor hereby authorizes the Collateral Agent to) modify this Agreement, as appropriate, by amending Annex H to include such information.

 

4.9                               Collateral in Possession of Third Party.  Without limiting the generality of any other provision of this Agreement, each Pledgor agrees that it shall not permit any Collateral consisting of an NDA, regulatory approvals, clinical studies or Intellectual Property related to a Material Product to be in the possession of any bailee, warehouseman, agent, processor or other third party at any time unless such bailee or other Person (i) shall have been notified of the security interest created by this Agreement and (ii) such Pledgor shall have used commercially reasonable efforts to have such bailee or other Person execute a written agreement with the Collateral Agent pursuant to which it (1) acknowledges that it is holding such Collateral for the benefit of the Collateral Agent and subject to such security interest and to the instructions of the Collateral Agent and (2) agrees to waive and release or subordinate any Lien (whether arising by operation of law or otherwise) it may have with respect to such Collateral, such agreement to be in form and substance reasonably satisfactory to the Collateral Agent.  The Borrower agrees to pay any reasonable and documented out-of-pocket costs and expenses incurred by the Collateral Agent in obtaining the agreement specified in the foregoing clause (ii).

 

4.10                        Commercial Tort Claims.  Each Pledgor agrees that it will, promptly upon the filing of any suit, action or proceeding relating to any Commercial Tort Claim involving damages in excess of [***] in its favor, furnish to the Collateral Agent a description thereof meeting the requirements of Section 9-108(e) of the Uniform Commercial Code, execute and deliver such documents, financing statements and other instruments, and take such other action, as the Collateral Agent may reasonably request in order to include such Commercial Tort Claim as Collateral hereunder and to perfect the security interest of the Collateral Agent therein.

 

4.11                        Protection of Security Interest.  Subject to Section 5.12 of the Note Purchase Agreement, each Pledgor agrees that it will, at its own cost and expense, take any and all actions necessary to warrant and defend the right, title and interest of the Secured Parties in and to the Collateral against the claims and demands of all other Persons.

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

13











 

ARTICLE V

 

CERTAIN PROVISIONS RELATING TO PLEDGED INTERESTS

 

5.1                               After-Acquired Equity Interests; Ownership.

 

(a)                                 Subject to Section 5.9 of the Note Purchase Agreement, if any Pledgor shall, at any time and from time to time after the date hereof, acquire any additional Capital Stock in any Person of the types described in the definition of the term “Pledged Interests,” the same shall be automatically deemed to be Pledged Interests hereunder, and to be pledged to the Collateral Agent pursuant to Section 2.1, and such Pledgor will pledge and deposit the same with the Collateral Agent and deliver to the Collateral Agent any certificates therefor, together with undated stock powers or other necessary instruments of transfer or assignment, duly executed in blank and in form and substance reasonably satisfactory to the Collateral Agent, together with such other certificates and instruments as the Collateral Agent may reasonably request (including Uniform Commercial Code financing statements or appropriate amendments thereto), and will promptly thereafter deliver to the Collateral Agent a fully completed and duly executed amendment to this Agreement in the form of Exhibit D (each, a “Pledge Amendment”) in respect thereof.  Each Pledgor hereby authorizes the Collateral Agent to attach each such Pledge Amendment to this Agreement, and agrees that all such Collateral listed on any Pledge Amendment shall for all purposes be deemed Collateral hereunder and shall be subject to the provisions hereof; provided that the failure of any Pledgor to execute and deliver any Pledge Amendment with respect to any such additional Collateral as required hereinabove shall not impair the security interest of the Collateral Agent in such Collateral or otherwise adversely affect the rights and remedies of the Collateral Agent hereunder with respect thereto.

 

(b)                                 If any Pledged Interests (whether now owned or hereafter acquired) included in the Collateral are “uncertificated securities” within the meaning of the Uniform Commercial Code or are otherwise not evidenced by any certificate or instrument, each applicable Pledgor will promptly notify the Collateral Agent thereof and will promptly take and cause to be taken, and will (if the issuer of such uncertificated securities is a Person other than a Subsidiary of the Borrower) use best efforts to cause the issuer to take, all actions required under Articles 8 and 9 of the Uniform Commercial Code and any other applicable law, to enable the Collateral Agent to acquire “control” of such uncertificated securities (within the meaning of such term under Section 8-106 (or its successor provision) of the Uniform Commercial Code) and as may be otherwise necessary to perfect the security interest of the Collateral Agent therein.

 

5.2                               Voting Rights.  So long as no Event of Default shall have occurred and be continuing, each Pledgor shall be entitled to exercise all voting and other consensual rights pertaining to its Pledged Interests (subject to its obligations under Section 5.1(a)), and for that purpose the Collateral Agent will execute and deliver or cause to be executed and delivered to each applicable Pledgor all such proxies and other instruments as such Pledgor may reasonably request in writing to enable such Pledgor to exercise such voting and other consensual rights; provided, however, that no Pledgor will cast any vote, give any consent, waiver or ratification, or take or fail to take any action, in any manner that would reasonably be expected to, violate or be inconsistent with any of the terms of this Agreement, the Note Purchase Agreement or any other Credit Document or have the effect of materially and adversely impairing the position or interests of the Secured Parties.

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

14











 

5.3                               Dividends and Other Distributions.  All interest, income, dividends, distributions and other amounts payable in cash in respect of the Pledged Interests may be paid to and retained by the Pledgors; provided, however, that all such interest, income, dividends, distributions and other amounts shall, upon the written election of the Collateral Agent after the occurrence and during the continuance of an Event of Default, be paid to the Collateral Agent and retained by it as part of the Collateral (except to the extent applied upon receipt to the repayment of the Secured Obligations).  The Collateral Agent shall also be entitled at all times (whether or not during the continuance of an Event of Default), to receive directly, and to retain as part of the Collateral, (i) all additional Pledged Interests or other securities or property (other than cash) paid or payable or distributed or distributable in respect of any Pledged Interests in connection with any noncash dividend, distribution, return of capital, spin-off, stock split, split-up, reclassification, combination of shares or interests or similar rearrangement, and (ii) without affecting any restrictions against such actions contained in the Note Purchase Agreement, all additional Pledged Interests or other securities or property (including cash) paid or payable or distributed or distributable in respect of any Pledged Interests in connection with any consolidation, merger, exchange of securities, liquidation or other reorganization.  All interest, income, dividends, distributions or other amounts that are received by any Pledgor in violation of the provisions of this Section 5.3 shall be received in trust for the benefit of the Collateral Agent, shall be segregated from other property or funds of such Pledgor and shall be forthwith delivered to the Collateral Agent as Collateral in the same form as so received (with any necessary endorsements).  Any and all property paid over to or received by the Collateral Agent pursuant to the provisions of this Section 5.3 shall be retained by the Collateral Agent in a Collateral Account (as hereinafter defined) upon receipt of such property and shall be applied in accordance with the provisions of Section 6.2.  The Collateral Agent shall, within [***] after all Events of Default have been cured or waived, repay to each applicable Pledgor all cash interest, income, dividends, distributions and other amounts that such Pledgor would otherwise be permitted to retain pursuant to the provisions of this Section 5.3 and that remain in such Collateral Account.

 

ARTICLE VI

 

REMEDIES

 

6.1                               Remedies.  If an Event of Default shall have occurred and be continuing, the Collateral Agent shall be entitled to exercise in respect of the Collateral all of its rights, powers and remedies provided for herein or otherwise available to it under any other Credit Document, by law, in equity or otherwise, including all rights and remedies of a secured party under the Uniform Commercial Code, and shall be entitled in particular, but without limitation of the foregoing, to exercise the following rights, which each Pledgor agrees to be commercially reasonable:

 

(a)                                 To notify any or all account debtors or obligors under any Accounts, Contracts or other Collateral of the security interest in favor of the Collateral Agent created hereby and to direct all such Persons to make payments of all amounts due thereon or thereunder directly to the Collateral Agent or to an account designated by the Collateral Agent; and in such instance and from and after such notice, all amounts and Proceeds (including wire transfers, checks and other Instruments) received by any Pledgor in respect of any Accounts, Contracts or other Collateral shall be received in trust for the benefit of the Collateral Agent hereunder, shall be segregated from the other funds of such Pledgor and shall be forthwith deposited into such account or paid

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

15











 

over or delivered to the Collateral Agent in the same form as so received (with any necessary endorsements or assignments), to be held as Collateral and applied to the Secured Obligations as provided herein; and by this provision, each Pledgor irrevocably authorizes and directs each Person who is or shall be a party to or liable for the performance of any Contract, upon receipt of notice from the Collateral Agent to the effect that an Event of Default has occurred and is continuing, to attorn to or otherwise recognize the Collateral Agent as owner under such Contract and to pay, observe and otherwise perform the obligations under such Contract to or for the Collateral Agent or the Collateral Agent’s designee as though the Collateral Agent or such designee were such Pledgor named therein, and to do so until otherwise notified by the Collateral Agent;

 

(b)                                 To take possession of, receive, endorse, assign and deliver, in its own name or in the name of any Pledgor, all checks, notes, drafts and other Instruments relating to any Collateral, including receiving and opening of all mail addressed to any Pledgor concerning Accounts and other Collateral; to verify with account debtors or other contract parties the validity, amount or any other matter relating to any Accounts or other Collateral, in its own name or in the name of any Pledgor; to accelerate any Indebtedness or other obligation constituting Collateral that may be accelerated in accordance with its terms; to take or bring all actions and suits deemed necessary or appropriate to effect collections and to enforce payment of any Accounts or other Collateral; to settle, compromise or release in whole or in part any amounts owing on Accounts or other Collateral; and to extend the time of payment of any and all Accounts or other amounts owing under any Collateral and to make allowances and adjustments with respect thereto, all in the same manner and to the same extent as any Pledgor might have done;

 

(c)                                  To notify any or all depository institutions with which any Deposit Accounts are maintained and which Deposit Accounts are subject to control in favor of the Collateral Agent to remit and transfer all monies, securities and other property on deposit in such Deposit Accounts or deposited or received for deposit thereafter to the Collateral Agent, for deposit in a Collateral Account or such other accounts as may be designated by the Collateral Agent, for application to the Secured Obligations as provided herein;

 

(d)                                 To transfer to or register in its name or the name of any of its Collateral Agents or nominees all or any part of the Collateral, without notice to any Pledgor and with or without disclosing that such Collateral is subject to the security interest created hereunder;

 

(e)                                  To require any Pledgor to, and each Pledgor hereby agrees that it will at its expense and upon request of the Collateral Agent forthwith, assemble all or any part of the Collateral as directed by the Collateral Agent and make it available to the Collateral Agent at a place designated by the Collateral Agent (subject to any restrictions under applicable law relating to the possession and sale or other disposition of any controlled substances);

 

(f)                                   To enter and remain upon the premises of any Pledgor and take possession of all or any part of the Collateral, with or without judicial process; to use the materials, services, books and records of any Pledgor for the purpose of liquidating or collecting the Collateral, whether by foreclosure, auction or otherwise; and to remove the same to the premises of the Collateral Agent or any designated agent for such time as the Collateral Agent may desire, in

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

16











 

order to effectively collect or liquidate the Collateral (in each case, subject to customary limitations relating to the possession and sale or other disposition of any controlled substances);

 

(g)                                  To exercise (i) all voting, consensual and other rights and powers pertaining to the Pledged Interests (whether or not transferred into the name of the Collateral Agent), at any meeting of shareholders, partners, members or otherwise, and (ii) any and all rights of conversion, exchange, subscription and any other rights, privileges or options pertaining to the Pledged Interests as if it were the absolute owner thereof (including, without limitation, the right to exchange at its discretion any and all of the Pledged Interests upon the merger, consolidation, reorganization, reclassification, combination of shares or interests, similar rearrangement or other similar fundamental change in the structure of the applicable issuer, or upon the exercise by any Pledgor or the Collateral Agent of any right, privilege or option pertaining to such Pledged Interests), and in connection therewith, the right to deposit and deliver any and all of the Pledged Interests with any committee, depositary, transfer agent, registrar or other designated agency upon such terms and conditions as the Collateral Agent may determine, and give all consents, waivers and ratifications in respect of the Pledged Interests, all without liability except to account for any property actually received by it, but the Collateral Agent shall have no duty to exercise any such right, privilege or option or give any such consent, waiver or ratification and shall not be responsible for any failure to do so or delay in so doing; and for the foregoing purposes each Pledgor will promptly execute and deliver or cause to be executed and delivered to the Collateral Agent, upon request, all such proxies and other instruments as the Collateral Agent may reasonably request to enable the Collateral Agent to exercise such rights and powers; AND IN FURTHERANCE OF THE FOREGOING AND WITHOUT LIMITATION THEREOF, DURING THE CONTINUATION OF AN EVENT OF DEFAULT, EACH PLEDGOR HEREBY IRREVOCABLY CONSTITUTES AND APPOINTS THE COLLATERAL AGENT AS THE TRUE AND LAWFUL PROXY AND ATTORNEY-IN-FACT OF SUCH PLEDGOR, WITH FULL POWER OF SUBSTITUTION IN THE PREMISES, TO EXERCISE ALL SUCH VOTING, CONSENSUAL AND OTHER RIGHTS AND POWERS TO WHICH ANY HOLDER OF ANY PLEDGED INTERESTS WOULD BE ENTITLED BY VIRTUE OF HOLDING THE SAME, WHICH PROXY AND POWER OF ATTORNEY, BEING COUPLED WITH AN INTEREST, IS IRREVOCABLE AND SHALL BE EFFECTIVE FOR SO LONG AS THIS AGREEMENT SHALL BE IN EFFECT; and

 

(h)                                 To sell, resell, assign and deliver, in its sole discretion, all or any of the Collateral, in one or more parcels (subject to any restrictions under applicable law relating to the possession and sale or other disposition of any controlled substances and any legal or statutory restrictions applicable to the transfer of any Collateral constituting Regulatory Approvals), on any securities exchange on which any Pledged Interests may be listed, at public or private sale, at any of the Collateral Agent’s offices or elsewhere, for cash, upon credit or for future delivery, at such time or times and at such price or prices and upon such other terms as the Collateral Agent may deem satisfactory.  If any of the Collateral is sold by the Collateral Agent upon credit or for future delivery, the Collateral Agent shall not be liable for the failure of the purchaser to purchase or pay for the same and, in the event of any such failure, the Collateral Agent may resell such Collateral.  In no event shall any Pledgor be credited with any part of the Proceeds of sale of any Collateral until and to the extent cash payment in respect thereof has actually been received by the Collateral Agent.  Each purchaser at any such sale shall hold the property sold absolutely, free from any claim or right of whatsoever kind, including any equity or right of redemption of

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

17











 

any Pledgor, and each Pledgor hereby expressly waives all rights of redemption, stay or appraisal, and all rights to require the Collateral Agent to marshal any assets in favor of such Pledgor or any other party or against or in payment of any or all of the Secured Obligations, that it has or may have under any rule of law or statute now existing or hereafter adopted.  No demand, presentment, protest, advertisement or notice of any kind (except any notice required by law, as referred to below), all of which are hereby expressly waived by each Pledgor, shall be required in connection with any sale or other disposition of any part of the Collateral.  If any notice of a proposed sale or other disposition of any part of the Collateral shall be required under applicable law, the Collateral Agent shall give the applicable Pledgor at least [***] prior notice of the time and place of any public sale and of the time after which any private sale or other disposition is to be made, which notice each Pledgor agrees is commercially reasonable.  The Collateral Agent shall not be obligated to make any sale of Collateral if it shall determine not to do so, regardless of the fact that notice of sale may have been given.  The Collateral Agent may, without notice or publication, adjourn any public or private sale or cause the same to be adjourned from time to time by announcement at the time and place fixed for sale, and such sale may, without further notice, be made at the time and place to which the same was so adjourned.  Upon each public sale and, to the extent permitted by applicable law, upon each private sale, the Collateral Agent may purchase all or any of the Collateral being sold, free from any equity, right of redemption or other claim or demand, and may make payment therefor by endorsement and application (without recourse) of the Secured Obligations in lieu of cash as a credit on account of the purchase price for such Collateral.

 

6.2                               Application of Proceeds.

 

(a)                                 All Proceeds collected by the Collateral Agent upon any sale, other disposition of or realization upon any of the Collateral, together with all other moneys received by the Collateral Agent hereunder, shall be applied in accordance with Section 2.8 of the Note Purchase Agreement.

 

(b)                                 In the event that the proceeds of any such sale, disposition or realization are insufficient to pay all amounts to which the Secured Parties are legally entitled, the Pledgors shall be jointly and severally liable for the deficiency, together with interest thereon at the highest rate specified in any applicable Credit Document for interest on overdue principal or such other rate as shall be fixed by applicable law, together with the costs of collection and all other fees, costs and expenses payable hereunder, subject to Section 9.1 of the Note Purchase Agreement.

 

(c)                                  Upon any sale of any Collateral hereunder by the Collateral Agent (whether by virtue of the power of sale herein granted, pursuant to judicial proceeding, or otherwise), the receipt of the Collateral Agent or the officer making the sale shall be a sufficient discharge to the purchaser or purchasers of the Collateral so sold, and such purchaser or purchasers shall not be obligated to see to the application of any part of the purchase money paid over to the Collateral Agent or such officer or be answerable in any way for the misapplication thereof.

 

6.3                               Collateral Accounts.  Upon the occurrence and during the continuance of an Event of Default, the Collateral Agent shall have the right to cause to be established and maintained, at its principal office or such other location or locations as it may establish from time to time in its discretion, one or more accounts (collectively, “Collateral Accounts”) for the

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

18











 

collection of cash Proceeds of the Collateral.  Such Proceeds, when deposited, shall continue to constitute Collateral for the Secured Obligations and shall not constitute payment thereof until applied as herein provided.  The Collateral Agent shall have sole dominion and control over all funds deposited in any Collateral Account, and such funds may be withdrawn therefrom only by the Collateral Agent.  Upon the occurrence and during the continuance of an Event of Default, the Collateral Agent shall have the right to (and, if directed by the Purchasers pursuant to the Note Purchase Agreement, shall) apply amounts held in the Collateral Accounts in payment of the Secured Obligations in the manner provided for in Section 6.2.

 

6.4                               Grant of License.  Upon the occurrence and during the continuance of an Event of Default, each Pledgor hereby grants to the Collateral Agent a non-exclusive license (exercisable without payment of royalty or other compensation to any Pledgor) to use, license or sublicense any Patent Collateral, Trademark Collateral or Copyright Collateral now owned or licensed or hereafter acquired or licensed by such Pledgor, wherever the same may be located throughout the world, for such term or terms, on such conditions and in such manner as the Collateral Agent shall determine, whether general, special or otherwise, and whether on an exclusive or nonexclusive basis, and including in such license reasonable access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof; provided, however that nothing in this Section 6.4  shall require Pledgors to grant any license in any Patent Collateral, Trademark Collateral or Copyright Collateral to the extent a grant of such license or sublicense would violate any Patent License, Trademark License or Copyright License applicable to such Collateral.  The use of such license or sublicense by the Collateral Agent shall be exercised, at the option of the Collateral Agent, only upon the occurrence and during the continuation of an Event of Default; provided that any license, sublicense or other transaction entered into by the Collateral Agent in accordance herewith shall be binding upon each applicable Pledgor notwithstanding any subsequent cure of an Event of Default.

 

6.5                               Private Sales.

 

(a)                                 Each Pledgor recognizes that the Collateral Agent may be compelled, at any time after the occurrence and during the continuance of an Event of Default, to conduct any sale of all or any part of the Pledged Interests without registering or qualifying such Pledged Interests under the Securities Act and/or any applicable state securities laws in effect at such time.  Each Pledgor acknowledges that any such private sales may be made in such manner and under such circumstances as the Collateral Agent may deem necessary or advisable in its sole and absolute discretion, including at prices and on terms that might be less favorable than those obtainable through a public sale without such restrictions (including, without limitation, a public offering made pursuant to a registration statement under the Securities Act), and, notwithstanding such circumstances, agrees that any such sale shall not be deemed not to have been made in a commercially reasonable manner solely because it was conducted as a private sale, and agrees that the Collateral Agent shall have no obligation to conduct any public sales and no obligation to delay the sale of any Pledged Interests for the period of time necessary to permit its registration for public sale under the Securities Act and applicable state securities laws, and shall not have any responsibility or liability as a result of its election so not to conduct any such public sales or delay the sale of any Pledged Interests, notwithstanding the possibility that a substantially higher price might be realized if the sale were deferred until after such registration.

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

19












 

Each Pledgor hereby waives any claims against the Collateral Agent or any other Secured Party arising by reason of the fact that the price at which any Pledged Interests may have been sold at any private sale was less than the price that might have been obtained at a public sale or was less than the aggregate amount of the Secured Obligations, even if the Collateral Agent accepts the first offer received and does not offer such Pledged Interests to more than one offeree.

 

(b)                                 Each Pledgor agrees to use commercially reasonable efforts to do or cause to be done all such other acts as may be necessary to make such sale or sales of any portion of the Collateral pursuant to Section 6.1 and this Section 6.5 valid and binding and in compliance with all applicable Requirements of Law.  Each Pledgor agrees that a breach of any of the covenants contained in this Section 6.5 will cause irreparable injury to the Collateral Agent and the other Secured Parties, that the Collateral Agent and the other Secured Parties have no adequate remedy at law in respect of such breach and, as a consequence, that each and every covenant contained in this Section 6.5 shall be specifically enforceable against the Pledgors.

 

6.6                               The Pledgors Remain Liable.  Notwithstanding anything herein to the contrary, (i) each Pledgor shall remain liable under all Contracts to which it is a party included within the Collateral (including, without limitation, all Ownership Agreements) to perform all of its obligations thereunder to the same extent as if this Agreement had not been executed, (ii) the exercise by the Collateral Agent of any of its rights or remedies hereunder shall not release any Pledgor from any of its obligations under any of such Contracts, and (iii) except as specifically provided for hereinbelow, the Collateral Agent shall not have any obligation or liability by reason of this Agreement under any of such Contracts, nor shall the Collateral Agent be obligated to perform any of the obligations or duties of any Pledgor thereunder or to take any action to collect or enforce any claim for payment assigned hereunder.  The powers, rights and remedies conferred on the Collateral Agent hereunder are solely to protect its interest and privilege in such Contracts, as Collateral, and shall not impose any duty upon it to exercise any such powers, rights or remedies.

 

6.7                               Waivers.  Each Pledgor, to the greatest extent not prohibited by applicable law, hereby (i) agrees that it will not invoke, claim or assert the benefit of any rule of law or statute now or hereafter in effect (including, without limitation, any right to prior notice or judicial hearing in connection with the Collateral Agent’s possession, custody or disposition of any Collateral or any appraisal, valuation, stay, extension, moratorium or redemption law), or take or omit to take any other action, that would reasonably be expected to have the effect of delaying, impeding or preventing the exercise of any rights and remedies in respect of the Collateral, the absolute sale of any of the Collateral or the possession thereof by any purchaser at any sale thereof, and waives the benefit of all such laws and statutes and further agrees that it will not hinder, delay or impede the execution of any power granted hereunder to the Collateral Agent, but that it will permit the execution of every such power as though no such laws or statutes were in effect, (ii) waives all rights that it has or may have under any rule of law or statute now existing or hereafter adopted to require the Collateral Agent to marshal any Collateral or other assets in favor of such Pledgor or any other party or against or in payment of any or all of the Secured Obligations, and (iii) waives all rights that it has or may have under any rule of law or statute now existing or hereafter adopted to demand, presentment, protest, advertisement or notice of any kind (except notices expressly provided for herein).  In addition, each Pledgor

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

20











 

waives any and all rights of contribution or subrogation upon the sale or disposition of all or any portion of the Collateral by the Collateral Agent.

 

ARTICLE VII

 

THE COLLATERAL AGENT

 

7.1                               The Collateral Agent; Standard of Care.  The Collateral Agent will hold all items of the Collateral at any time received under this Agreement in accordance with the provisions hereof and will exercise reasonable care with respect thereto.  The obligations of the Collateral Agent as holder of the Collateral and interests therein and with respect to the disposition thereof, and otherwise under this Agreement and the other Credit Documents, are only those expressly set forth in this Agreement and the other Credit Documents.  The Collateral Agent shall act hereunder at the direction, or with the consent, of the Purchasers on the terms and conditions set forth in the Note Purchase Agreement.  The powers conferred on the Collateral Agent hereunder are solely to protect its interest, on behalf of the Secured Parties, in the Collateral, and shall not impose any duty upon it to exercise any such powers.  Except for treatment of the Collateral in its possession in a manner substantially equivalent to that which the Collateral Agent, in its individual capacity, accords its own property of a similar nature, which standard shall in no event be less than reasonable care, and the accounting for moneys actually received by it hereunder, the Collateral Agent shall have no duty as to any Collateral or as to the taking of any necessary steps to preserve rights against prior parties or any other rights pertaining to the Collateral.  Neither the Collateral Agent nor any other Secured Party shall be liable to any Pledgor (i) for any loss or damage sustained by such Pledgor, or (ii) for any loss, damage, depreciation or other diminution in the value of any of the Collateral that may occur as a result of or in connection with or that is in any way related to any exercise by the Collateral Agent or any other Secured Party of any right or remedy under this Agreement, any failure to demand, collect or realize upon any of the Collateral or any delay in doing so, or any other act or failure to act on the part of the Collateral Agent or any other Secured Party, except to the extent that the same is caused by its own gross negligence or willful misconduct.

 

7.2                               Further Assurances; Attorney-in-Fact.

 

(a)                                 Each Pledgor hereby irrevocably authorizes the Collateral Agent at any time and from time to time to file in any filing office in any Uniform Commercial Code jurisdiction any financing statements and amendments thereto that (a) indicate the Collateral (i) as all assets of such Pledgor or words of similar effect, regardless of whether any particular asset included within the Collateral falls within the scope of Article 9 of the Uniform Commercial Code of any such jurisdiction, or (ii) as being of an equal or lesser scope or with greater detail, and (b) provide any other information required by Part 5 of Article 9 of the Uniform Commercial Code for the sufficiency or filing office acceptance of any financing statement or amendment.

 

(b)                                 Each Pledgor agrees that it will do such further acts and things (including, without limitation, making any notice filings with state tax or revenue authorities required to be made by account creditors in order to enforce any Accounts in such state) and execute and deliver to the Collateral Agent such additional conveyances, assignments, agreements and instruments as the Collateral Agent may reasonably deem necessary to perfect, establish, confirm and maintain the security interest and Lien provided for herein, to carry out the purposes of this Agreement or to

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

21











 

further assure and confirm unto the Collateral Agent its rights, powers and remedies hereunder (in each case, subject to Section 5.12 of the Note Purchase Agreement).

 

(c)                                  Each Pledgor hereby irrevocably appoints the Collateral Agent its lawful attorney-in-fact, with full authority in the place and stead of such Pledgor and in the name of such Pledgor, the Collateral Agent or otherwise, and with full power of substitution in the premises (which power of attorney, being coupled with an interest, is irrevocable for so long as this Agreement shall be in effect), from time to time in the Collateral Agent’s discretion after the occurrence and during the continuance of an Event of Default (except for the actions described in clause (i) below, which may be taken by the Collateral Agent without regard to whether an Event of Default has occurred) to take any action and to execute any instruments that the Collateral Agent may deem necessary or advisable to accomplish the purpose of this Agreement, including, without limitation:

 

(i)                                     to sign the name of such Pledgor on any financing statement, continuation statement, notice or other similar document that, in the Collateral Agent’s reasonable judgment, is necessary in order to perfect or continue perfected the security interest granted under this Agreement;

 

(ii)                                  to ask, demand, collect, sue for, recover, compound, receive and give acquittance and receipts for moneys due and to become due under or in respect of any of the Collateral;

 

(iii)                               to receive, endorse and collect any checks, drafts, Instruments, Chattel Paper and other orders for the payment of money made payable to such Pledgor representing any interest, income, dividend, distribution or other amount payable in respect of any of the Collateral and to give full discharge for the same;

 

(iv)                              to obtain, maintain and adjust any property or casualty insurance required to be maintained by such Pledgor under Section 5.7 of the Note Purchase Agreement and direct the payment of proceeds thereof to the Collateral Agent;

 

(v)                                 to pay or discharge taxes, Liens or other encumbrances levied or placed on or threatened against the Collateral, the legality or validity thereof and the amounts necessary to discharge the same to be determined by the Collateral Agent in its sole discretion, any such payments made by the Collateral Agent to become Secured Obligations of the Pledgors to the Collateral Agent, due and payable immediately and without demand;

 

(vi)                              to file any claims or take any action or institute any proceedings that the Collateral Agent may deem necessary or advisable for the collection of any of the Collateral or otherwise to enforce the rights of the Collateral Agent with respect to any of the Collateral; and

 

(vii)                           to use, sell, assign, transfer, pledge, make any agreement with respect to or otherwise deal with any and all of the Collateral as fully and completely as though the Collateral Agent were the absolute owner of the Collateral for all purposes, and to do from time to time, at the Collateral Agent’s option and the Pledgors’ expense, all other

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

22











 

acts and things deemed necessary by the Collateral Agent to protect, preserve or realize upon the Collateral and to more completely carry out the purposes of this Agreement.

 

(d)                                 If any Pledgor fails to perform any covenant or agreement contained in this Agreement after written request to do so by the Collateral Agent (provided that no such request shall be necessary at any time after the occurrence and during the continuance of an Event of Default), the Collateral Agent may itself perform, or cause the performance of, such covenant or agreement and may take any other action that it deems necessary and appropriate for the maintenance and preservation of the Collateral or its security interest therein, and the reasonable expenses so incurred in connection therewith shall be payable by the Pledgors under Section 8.1.

 

ARTICLE VIII

 

MISCELLANEOUS

 

8.1                               Indemnity and Expenses.  Subject to Section 9.1 or 9.2 of the Note Purchase Agreement, the Pledgors agree jointly and severally to indemnify and hold harmless the Collateral Agent, each other Secured Party and each of their Related Parties from and against any and all claims, damages, demands, losses, obligations, judgments and liabilities (including, without limitation, reasonable and documented out of pocket attorneys’ fees and expenses) in any way arising out of or in connection with this Agreement and the transactions contemplated hereby, except to the extent the same shall arise as a result of the gross negligence or willful misconduct of the party seeking to be indemnified.

 

8.2                               No Waiver.  The rights and remedies of the Secured Parties expressly set forth in this Agreement and the other Credit Documents are cumulative and in addition to, and not exclusive of, all other rights and remedies available at law, in equity or otherwise.  No failure or delay on the part of any Secured Party in exercising any right, power or privilege shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power or privilege preclude any other or further exercise thereof or the exercise of any other right, power or privilege or be construed to be a waiver of any Default or Event of Default.  No course of dealing between the Pledgors and the Secured Parties or their agents or employees shall be effective to amend, modify or discharge any provision of this Agreement or any other Credit Document or to constitute a waiver of any Default or Event of Default.  No notice to or demand upon any Pledgor in any case shall entitle such Pledgor or any other Pledgor to any other or further notice or demand in similar or other circumstances or constitute a waiver of the right of any Secured Party to exercise any right or remedy or take any other or further action in any circumstances without notice or demand.

 

8.3                               Enforcement.  By its acceptance of the benefits of this Agreement, each Purchaser agrees that this Agreement may be enforced only by the Collateral Agent, acting upon the instructions or with the consent of the Purchasers as provided for in the Note Purchase Agreement, and that no Purchaser shall have any right individually to enforce or seek to enforce this Agreement or to realize upon any Collateral or other security given to secure the payment and performance of the Secured Obligations.

 

8.4                               Amendments, Waivers, etc.  No amendment, modification, waiver, discharge or termination of, or consent to any departure by any Pledgor from, any provision of this

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

23











 

Agreement, shall be effective unless in a writing signed by the Collateral Agent and such of the Purchasers as may be required under Section 9.10 of the Note Purchase Agreement to concur in the action then being taken, and then the same shall be effective only in the specific instance and for the specific purpose for which given.

 

8.5                               Continuing Security Interest; Term; Successors and Assigns; Assignment; Termination and Release; Survival.  This Agreement shall create a continuing security interest in the Collateral and shall secure the payment and performance of all of the Secured Obligations as the same may arise and be outstanding at any time and from time to time from and after the date hereof, and shall (i) remain in full force and effect until the occurrence of the Termination Requirements (as hereinafter defined), (ii) be binding upon and enforceable against each Pledgor and its successors and assigns (provided, however, that no Pledgor may sell, assign or transfer any of its rights, interests, duties or obligations hereunder without the prior written consent of the Purchasers) and (iii) inure to the benefit of and be enforceable by each Secured Party and its successors and assigns.  Upon any sale or other disposition by any Pledgor of any Collateral in a transaction expressly permitted hereunder or under or pursuant to the Note Purchase Agreement or any other applicable Credit Document, the Lien and security interest created by this Agreement in and upon such Collateral shall be automatically released, and upon the satisfaction of all of the Termination Requirements, this Agreement and the Lien and security interest created hereby shall terminate (provided, that the provisions of Section 6.7 shall survive the termination of this Agreement); and in connection with any such release or termination, the Collateral Agent, at the request and expense of the applicable Pledgor, will execute and deliver to such Pledgor such documents and instruments evidencing such release or termination as such Pledgor may reasonably request and will assign, transfer and deliver to such Pledgor, without recourse and without representation or warranty, such of the Collateral as may then be in the possession of the Collateral Agent (or, in the case of any partial release of Collateral, such of the Collateral so being released as may be in its possession).  All representations, warranties, covenants and agreements herein shall survive the execution and delivery of this Agreement and any Pledgor Accession.  For purposes of this Agreement, “Termination Requirements” means (x) the payment in full in cash of the Secured Obligations (other than contingent and indemnification obligations not then due and payable), and (y) the termination of the Commitments.

 

8.6                               Additional Pledgors.  Each Pledgor recognizes that the provisions of the Note Purchase Agreement require certain Persons that become Subsidiaries of the Borrower, and that are not already parties hereto, to execute and deliver a Pledgor Accession, whereupon each such Person shall become a Pledgor hereunder with the same force and effect as if originally a Pledgor hereunder on the date hereof, and agrees that its obligations hereunder shall not be discharged, limited or otherwise affected by reason of the same, or by reason of the Collateral Agent’s actions in effecting the same or in releasing any Pledgor hereunder, in each case without the necessity of giving notice to or obtaining the consent of such Pledgor or any other Pledgor.

 

8.7                               Notices.  All notices and other communications provided for hereunder shall be given to the parties in the manner and subject to the other notice provisions set forth in the Note Purchase Agreement and the Guaranty Agreement.

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

24











 

8.8                               Governing Law.  This Agreement and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement shall be governed by, and construed in accordance with, the law of the State of New York.

 

8.9                               Severability.  To the extent any provision of this Agreement is prohibited by or invalid under the applicable law of any jurisdiction, such provision shall be ineffective only to the extent of such prohibition or invalidity and only in such jurisdiction, without prohibiting or invalidating such provision in any other jurisdiction or the remaining provisions of this Agreement in any jurisdiction.

 

8.10                        Construction.  The headings of the various articles, sections and subsections of this Agreement have been inserted for convenience only and shall not in any way affect the meaning or construction of any of the provisions hereof.  Unless the context otherwise requires, words in the singular include the plural and words in the plural include the singular.  The provisions of Section 1.3 of the Note Purchase Agreement are hereby incorporated by reference as if fully set forth herein.

 

8.11                        Counterparts.  This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.  Delivery of an executed counterpart of a signature page of this Agreement by facsimile or in electronic format (e.g., “pdf,” “tif” or similar file formats) shall be effective as delivery of a manually executed counterpart of this Agreement.

 

[The remainder of this page left blank intentionally.]

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

25











 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed under seal by their duly authorized officers as of the date first above written.

 

	
 
    	
DEPOMED, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   James A. Schoeneck
    
	
 
    	
Name:
    	
James   A. Schoeneck
    
	
 
    	
Title:
    	
President   and Chief Executive Officer
    
	
 
    	
 
    	
 
    
	
 
    	
DEPO   NF SUB, LLC
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   James A. Schoeneck
    
	
 
    	
Name:
    	
James   A. Schoeneck
    
	
 
    	
Title:
    	
President   and Chief Executive Officer
    
	
 
    	
 
    	
Depomed, Inc.,   Member
    


 

(signatures continued)

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

Signature Page to Pledge and Security Agreement

 











 

	
Accepted and agreed to:
    
	
 
    
	
DEERFIELD PRIVATE DESIGN FUND   III, L.P.,

as Collateral Agent
    	
 
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
Deerfield   Mgmt III, L.P.
    	
 
    
	
 
    	
General   Partner
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
J.E.   Flynn Capital III, LLC
    	
 
    
	
 
    	
 
    	
General   Partner
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/   David J. Clark
    	
 
    
	
Name:   
    	
David   J. Clark
    
	
Title:
    	
Authorized   Signatory
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

Signature Page to Pledge and Security Agreement

 











 

ANNEX A

 

FILING LOCATIONS

 

	
Name of Pledgor
    	
 
    	
Filing Location
    	
 
    
	
Depomed,   Inc.
    	
 
    	
Secretary   of state of the state of California
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Depo   NF Sub, LLC
    	
 
    	
Secretary   of state of the state of Delaware
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 











 

ANNEX B

 

JURISDICTION OF ORGANIZATION, CERTAIN LOCATIONS

 

Pledgor: Depomed, Inc.

 

Jurisdiction of Incorporation/Organization: California

 

Federal Tax ID no.: 94-3229046

 

Organizational ID no.: C1945473

 

Chief Executive Office Address: 7999 Gateway Boulevard, Suite 300, Newark, CA 94560

 

Locations of Records Related to Collateral: 7999 Gateway Boulevard, Suite 300, Newark, CA 94560

 

Locations of Equipment or Inventory:

 

	
Owner of Property
    	
 
    	
Address
    	
 
    	
Nature of Use of the
   Premises
    	
 
    	
Nature of Interest
    
	
BMR-Pacific Research   Center LP
    	
 
    	
7999   Gateway Boulevard, Suite 300
   Newark, CA 94560
    	
 
    	
Chief   Executive Office
    	
 
    	
Leasehold
    
	
Integrated   Commercialization Solutions, Inc.
    	
 
    	
345   International Blvd., Brooks, KY 4019; and
   5360 Capital Court #102, Reno, NV 89502
    	
 
    	
Logistics   provider facility
    	
 
    	
Third   party commercial outsourcing
    
	
DPT Lakewood, LLC
    	
 
    	
1200   Paco Way, Lakewood, NJ 08701
    	
 
    	
Lazanda®   manufacturer
    	
 
    	
Third   party manufacturer
    
	
Janssen Ortho LLC
    	
 
    	
State   Road 933 Km 0.1, Mamey Ward, Gurabo, PR 00778-9629
    	
 
    	
NUCYNTA®   manufacturer
    	
 
    	
Third   party manufacturer
    
	
Patheon Puerto   Rico, Inc.
    	
 
    	
Villa   Blanca Industrial Park, State Road No. 1, Km. 34.8, Jose Garrido Avenue,   Caguas, Puerto Rico 00725; and
   State Road 670, Km 2.7, State Road 670 Km 2.7, Manati, Puerto Rico 00674
    	
 
    	
Gralise®   manufacturer
    	
 
    	
Third   party manufacturer
    
	
Accucaps Industries   Limited
    	
 
    	
2125   Ambassador Drive, Windwor Ontario, Canada
    	
 
    	
Zipsor®   manufactuer
    	
 
    	
Third   party manufacturer
    
	
Mipharm S.p.A.
    	
 
    	
Via   B. Quaranta 12, Milan, Italy
    	
 
    	
CAMBIA®   manufacturer
    	
 
    	
Third   party manufacturer
    


 

Other places of business: N/A

 

Trade/fictitious or prior corporate names
 (last five years): N/A

 

Pledgor: Depo NF Sub, LLC

 

Jurisdiction of Incorporation/Organization: Delaware

 

Federal Tax ID no.: 47-3552536

 

Organizational ID no.: 5718378

 

Chief Executive Office Address: 7999 Gateway Boulevard, Suite 300, Newark, CA 94560

 

Locations of Records Related to Collateral: 7999 Gateway Boulevard, Suite 300, Newark, CA 94560

 

Locations of Equipment or Inventory:

 

	
Owner of Property
    	
 
    	
Address
    	
 
    	
Nature of Use of the
   Premises
    	
 
    	
Nature of Interest
    
	
BMR-Pacific Research   Center LP
    	
 
    	
7999   Gateway Boulevard, Suite 300
   Newark, CA 94560
    	
 
    	
Chief   Executive Office
    	
 
    	
Leasehold   of Depomed, Inc.
    


 

Other places of business: N/A

 

Trade/fictitious or prior corporate names
 (last five years): N/A

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 












 

ANNEX C

 

PLEDGED INTERESTS

 

	
Pledgor
    	
 
    	
Name of Issuer
    	
 
    	
Type of Interests
    	
 
    	
Certificate
   Number
    	
 
    	
No. of shares
   (if applicable)
    	
 
    	
Percentage of
   Outstanding
   Interests
   in Issuer
    	
 
    
	
Depomed, Inc.
    	
 
    	
Depo   DR Sub, LLC
    	
 
    	
Units
    	
 
    	
N/A
    	
 
    	
N/A
    	
 
    	
100%
    	
 
    
	
Depomed, Inc.
    	
 
    	
Depo   NF Sub, LLC
    	
 
    	
Units
    	
 
    	
1
    	
 
    	
100
    	
 
    	
100%
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 












 

ANNEX D

 

COPYRIGHTS AND COPYRIGHT APPLICATIONS

 

[N/A]

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

ANNEX E

 

PATENTS AND PATENT APPLICATIONS

 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2409552.00
    	
 
    	
23-Oct-2002
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
2786524.50
    	
 
    	
25-Oct-2002
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2003537608.00
    	
 
    	
25-Oct-2002
    	
 
    	
Abandoned
    	
 
    	
2005507000
    	
 
    	
10-Mar-2005
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
PA/A/2004/003930
    	
 
    	
25-Oct-2002
    	
 
    	
Abandoned
    	
 
    	
P04/586F
    	
 
    	
01-Dec-2004
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2002/034297
    	
 
    	
25-Oct-2002
    	
 
    	
NAT PHASE
    	
 
    	
WO 2003/035041
    	
 
    	
01-May-2003
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
TW
    	
 
    	
Depomed, Inc.
    	
 
    	
91124776.00
    	
 
    	
24-Oct-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
I324075
    	
 
    	
01-May-2010
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
10/045816
    	
 
    	
25-Oct-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
10/024932
    	
 
    	
18-Dec-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
10/769574
    	
 
    	
29-Jan-2004
    	
 
    	
Granted
    	
 
    	
US2004-0185105A1
    	
 
    	
23-Sep-2004
    	
 
    	
7976870
    	
 
    	
12-Jul-2011
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/153211
    	
 
    	
03-Jun-2011
    	
 
    	
Pending
    	
 
    	
US-2011-0301129-A1
    	
 
    	
08-Dec-2011
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/684155
    	
 
    	
21-Nov-2012
    	
 
    	
Pending
    	
 
    	
US 2013-0149379 A1
    	
 
    	
13-Jun-2013
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
10/280309
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
7438927
    	
 
    	
21-Oct-2008
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
10/903879
    	
 
    	
30-Jul-2004
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
7612112
    	
 
    	
03-Nov-2009
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
11/322448
    	
 
    	
29-Dec-2005
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
11/648134
    	
 
    	
29-Dec-2006
    	
 
    	
Abandoned
    	
 
    	
US-2007-0184104-A1
    	
 
    	
09-Aug-2007
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
61/065442
    	
 
    	
11-Feb-2008
    	
 
    	
Completed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
586185.00
    	
 
    	
09-Dec-2008
    	
 
    	
Abandoned
    	
 
    	
US-2009-0176882-A1
    	
 
    	
09-Jul-2009
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/239591
    	
 
    	
26-Sep-2008
    	
 
    	
Granted
    	
 
    	
US2009-0017121A1
    	
 
    	
15-Jan-2009
    	
 
    	
7731989
    	
 
    	
08-Jun-2010
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/563781
    	
 
    	
21-Sep-2009
    	
 
    	
Granted
    	
 
    	
US-2010-0034895-A1
    	
 
    	
11-Feb-2010
    	
 
    	
8119166
    	
 
    	
21-Feb-2012
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/749101
    	
 
    	
29-Mar-2010
    	
 
    	
Granted
    	
 
    	
US-2010-0247610-A1
    	
 
    	
30-Sep-2010
    	
 
    	
8252332
    	
 
    	
28-Aug-2012
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/111575
    	
 
    	
19-May-2011
    	
 
    	
Granted
    	
 
    	
US-2011-056223-A1
    	
 
    	
20-Oct-2011
    	
 
    	
8192756
    	
 
    	
05-Jun-2012
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/110522
    	
 
    	
18-May-2011
    	
 
    	
Pending
    	
 
    	
US-2011-0218246-A1
    	
 
    	
08-Sep-2011
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/301570
    	
 
    	
21-Nov-2011
    	
 
    	
Granted
    	
 
    	
US-2012-0128735-A1
    	
 
    	
24-May-2012
    	
 
    	
8475813
    	
 
    	
02-Jul-2013
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/270126
    	
 
    	
10-Oct-2011
    	
 
    	
Granted
    	
 
    	
US-2012-0027823-A1
    	
 
    	
02-Feb-2012
    	
 
    	
8440232
    	
 
    	
14-May-2013
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/301602
    	
 
    	
21-Nov-2011
    	
 
    	
Granted
    	
 
    	
US-2012-0064168-A1
    	
 
    	
15-Mar-2012
    	
 
    	
8529955
    	
 
    	
10-Sep-2013
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/301644
    	
 
    	
21-Nov-2011
    	
 
    	
Granted
    	
 
    	
US-2012-0064129-A1
    	
 
    	
15-Mar-2012
    	
 
    	
8231905
    	
 
    	
31-Jul-2012
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/396441
    	
 
    	
14-Feb-2012
    	
 
    	
Granted
    	
 
    	
US-2012-0148671-A1
    	
 
    	
14-Jun-2012
    	
 
    	
8409613
    	
 
    	
02-Apr-2013
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/553622
    	
 
    	
19-Jul-2012
    	
 
    	
Granted
    	
 
    	
US-2012-0282307-A1
    	
 
    	
08-Nov-2012
    	
 
    	
8333991
    	
 
    	
18-Dec-2012
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/560938
    	
 
    	
27-Jul-2012
    	
 
    	
Granted
    	
 
    	
US-2012-0289601-A1
    	
 
    	
15-Nov-2012
    	
 
    	
8333992
    	
 
    	
18-Dec-2012
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/854433
    	
 
    	
01-Apr-2013
    	
 
    	
Granted
    	
 
    	
US-2013-0224289-A1
    	
 
    	
29-Aug-2013
    	
 
    	
8580303
    	
 
    	
12-Nov-2013
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/943500
    	
 
    	
16-Jul-2013
    	
 
    	
Granted
    	
 
    	
US-2013-0302417-A1
    	
 
    	
14-Nov-2013
    	
 
    	
8802157
    	
 
    	
12-Aug-2014
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
14/075965
    	
 
    	
08-Nov-2013
    	
 
    	
Pending
    	
 
    	
US-2014-0072623-A1
    	
 
    	
13-Mar-2014
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/707961
    	
 
    	
07-Dec-2012
    	
 
    	
Granted
    	
 
    	
US 2013-0116320 A1
    	
 
    	
09-May-2013
    	
 
    	
8592481
    	
 
    	
26-Nov-2013
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
14/088058
    	
 
    	
22-Nov-2013
    	
 
    	
Abandoned
    	
 
    	
US-2014-0135395-A1
    	
 
    	
15-May-2014
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
14/328580
    	
 
    	
10-Jul-2014
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
2002348828.00
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
2002348828
    	
 
    	
20-Dec-2007
    	
 
    	
2002348828
    	
 
    	
03-Apr-2008
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
2005267738.00
    	
 
    	
29-Jul-2005
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2005267738
    	
 
    	
12-May-2011
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
2006332690.00
    	
 
    	
29-Dec-2006
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2464322.00
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2464322
    	
 
    	
11-Oct-2011
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2575555.00
    	
 
    	
29-Jul-2005
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2635466.00
    	
 
    	
26-Jun-2008
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CN
    	
 
    	
Depomed, Inc.
    	
 
    	
200680053410.60
    	
 
    	
25-Aug-2008
    	
 
    	
Abandoned
    	
 
    	
CN 101484153
    	
 
    	
15-Jul-2009
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
DK
    	
 
    	
Depomed, Inc.
    	
 
    	
2781665.10
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
1439825
    	
 
    	
28-Jul-2004
    	
 
    	
1439825
    	
 
    	
03-Apr-2013
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
2781665.10
    	
 
    	
25-Oct-2002
    	
 
    	
Opposed
    	
 
    	
1439825
    	
 
    	
28-Jul-2004
    	
 
    	
1439825
    	
 
    	
03-Apr-2013
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
5777053.90
    	
 
    	
29-Jul-2005
    	
 
    	
Intnd Aband
    	
 
    	
1773311
    	
 
    	
18-Apr-2007
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
6848292.60
    	
 
    	
29-Dec-2006
    	
 
    	
Abandoned
    	
 
    	
1976503
    	
 
    	
08-Oct-2008
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
10179051.70
    	
 
    	
25-Oct-2002
    	
 
    	
Abandoned
    	
 
    	
2266539
    	
 
    	
29-Dec-2010
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
FI
    	
 
    	
Depomed, Inc.
    	
 
    	
2781665.10
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
1439825
    	
 
    	
28-Jul-2004
    	
 
    	
1439825
    	
 
    	
03-Apr-2013
    	
 
    
	
FR
    	
 
    	
Depomed, Inc.
    	
 
    	
2781665.10
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
1439825
    	
 
    	
28-Jul-2004
    	
 
    	
1439825
    	
 
    	
03-Apr-2013
    	
 
    
	
DE
    	
 
    	
Depomed, Inc.
    	
 
    	
2781665.10
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
1439825
    	
 
    	
28-Jul-2004
    	
 
    	
1439825
    	
 
    	
03-Apr-2013
    	
 
    
	
IE
    	
 
    	
Depomed, Inc.
    	
 
    	
2781665.10
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
1439825
    	
 
    	
28-Jul-2004
    	
 
    	
1439825
    	
 
    	
03-Apr-2013
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2003-537607
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5421511
    	
 
    	
29-Nov-2013
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2007-523871
    	
 
    	
29-Jul-2005
    	
 
    	
Intnd Aband
    	
 
    	
2008-508317
    	
 
    	
21-Mar-2008
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2008-548754
    	
 
    	
29-Dec-2006
    	
 
    	
Intnd Aband
    	
 
    	
2009-522294
    	
 
    	
11-Jun-2009
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2010-179064
    	
 
    	
25-Oct-2002
    	
 
    	
Abandoned
    	
 
    	
2010-254713
    	
 
    	
11-Nov-2010
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
LU
    	
 
    	
Depomed, Inc.
    	
 
    	
2781665.10
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
1439825
    	
 
    	
28-Jul-2004
    	
 
    	
1439825
    	
 
    	
03-Apr-2013
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
PA/A/2004/003946
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
262974
    	
 
    	
10-Dec-2008
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
PA/a/2007/001187
    	
 
    	
29-Jul-2005
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
283341
    	
 
    	
25-Jan-2011
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
MX/a/2008/008504
    	
 
    	
27-Jun-2008
    	
 
    	
Abandoned
    	
 
    	
PA/a/2008/008504
    	
 
    	
29-Aug-2008
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
MC
    	
 
    	
Depomed, Inc.
    	
 
    	
2781665.10
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
1439825
    	
 
    	
28-Jul-2004
    	
 
    	
1439825
    	
 
    	
03-Apr-2013
    	
 
    
	
NL
    	
 
    	
Depomed, Inc.
    	
 
    	
2781665.10
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
1439825
    	
 
    	
28-Jul-2004
    	
 
    	
1439825
    	
 
    	
03-Apr-2013
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/IB2002/005440
    	
 
    	
25-Oct-2002
    	
 
    	
NAT PHASE
    	
 
    	
WO 2003/035040
    	
 
    	
01-May-2003
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2005/027170
    	
 
    	
29-Jul-2005
    	
 
    	
NAT PHASE
    	
 
    	
WO 2006/015294
    	
 
    	
09-Feb-2006
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2006/049511
    	
 
    	
29-Dec-2006
    	
 
    	
NAT PHASE
    	
 
    	
WO 2007/079195
    	
 
    	
12-Jul-2007
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
SE
    	
 
    	
Depomed, Inc.
    	
 
    	
2781665.10
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
1439825
    	
 
    	
28-Jul-2004
    	
 
    	
1439825
    	
 
    	
03-Apr-2013
    	
 
    
	
CH
    	
 
    	
Depomed, Inc.
    	
 
    	
2781665.10
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
1439825
    	
 
    	
28-Jul-2004
    	
 
    	
1439825
    	
 
    	
03-Apr-2013
    	
 
    
	
TW
    	
 
    	
Depomed, Inc.
    	
 
    	
91124777.00
    	
 
    	
24-Oct-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
I312285
    	
 
    	
21-Jul-2009
    	
 
    
	
TW
    	
 
    	
Depomed, Inc.
    	
 
    	
95149757.00
    	
 
    	
29-Dec-2006
    	
 
    	
Intnd Aband
    	
 
    	
200800155
    	
 
    	
01-Jan-2008
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
UK
    	
 
    	
Depomed, Inc.
    	
 
    	
2781665.10
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
1439825
    	
 
    	
28-Jul-2004
    	
 
    	
1439825
    	
 
    	
03-Apr-2013
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
10/280852
    	
 
    	
25-Oct-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
7413751
    	
 
    	
19-Aug-2008
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
2008282900.00
    	
 
    	
28-Jan-2010
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2008282900
    	
 
    	
04-Sep-2014
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2694602.00
    	
 
    	
26-Jan-2010
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CN
    	
 
    	
Depomed, Inc.
    	
 
    	
200880100816.40
    	
 
    	
27-Jan-2010
    	
 
    	
Abandoned
    	
 
    	
101888828
    	
 
    	
17-Nov-2010
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
8794829.50
    	
 
    	
25-Jul-2008
    	
 
    	
Pending
    	
 
    	
2192892
    	
 
    	
09-Jun-2010
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
HK
    	
 
    	
Depomed, Inc.
    	
 
    	
11104785.80
    	
 
    	
16-May-2011
    	
 
    	
Abandoned
    	
 
    	
1150759A
    	
 
    	
13-Jan-2012
    	
 
    	
 
    	
 
    	
 
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2010-519222
    	
 
    	
27-Jan-2010
    	
 
    	
Abandoned
    	
 
    	
2010-534721
    	
 
    	
11-Nov-2010
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
MX/a/2010/001071
    	
 
    	
27-Jan-2010
    	
 
    	
Abandoned
    	
 
    	
MX/a/2010/001071
    	
 
    	
01-Mar-2010
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2008/009139
    	
 
    	
25-Jul-2008
    	
 
    	
NAT PHASE
    	
 
    	
WO 2009/017716
    	
 
    	
05-Feb-2009
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
60/952501
    	
 
    	
27-Jul-2007
    	
 
    	
Completed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
60/967717
    	
 
    	
05-Sep-2007
    	
 
    	
Completed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/220747
    	
 
    	
25-Jul-2008
    	
 
    	
Pending
    	
 
    	
US-2009-0028941-A1
    	
 
    	
29-Jan-2009
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
8138698.00
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
729529
    	
 
    	
17-May-2001
    	
 
    
	
AT
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
998271
    	
 
    	
24-Aug-2005
    	
 
    
	
BE
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
998271
    	
 
    	
24-Aug-2005
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2290624.00
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2290624
    	
 
    	
05-Dec-2006
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
998271
    	
 
    	
24-Aug-2005
    	
 
    
	
FR
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
998271
    	
 
    	
24-Aug-2005
    	
 
    
	
DE
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
998271
    	
 
    	
24-Aug-2005
    	
 
    
	
GR
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
3055266
    	
 
    	
24-Aug-2005
    	
 
    
	
HK
    	
 
    	
Depomed, Inc.
    	
 
    	
106550.90
    	
 
    	
16-Oct-2000
    	
 
    	
Granted
    	
 
    	
1027298A
    	
 
    	
12-Jan-2001
    	
 
    	
1027298
    	
 
    	
09-Dec-2005
    	
 
    
	
IE
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
998271
    	
 
    	
24-Aug-2005
    	
 
    
	
IT
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
998271
    	
 
    	
24-Aug-2005
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
11-502756
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
4083818
    	
 
    	
22-Feb-2008
    	
 
    
	
KR
    	
 
    	
Depomed, Inc.
    	
 
    	
1019997011439.00
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
545480
    	
 
    	
17-Jan-2006
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
9911232.00
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
227488
    	
 
    	
27-Apr-2005
    	
 
    
	
NL
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
998271
    	
 
    	
24-Aug-2005
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US1998/011302
    	
 
    	
05-Jun-1998
    	
 
    	
NAT PHASE
    	
 
    	
1998/055107
    	
 
    	
10-Dec-1998
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PT
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
998271
    	
 
    	
24-Aug-2005
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
ES
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
998271
    	
 
    	
24-Aug-2005
    	
 
    
	
SE
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
998271
    	
 
    	
24-Aug-2005
    	
 
    
	
CH
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
998271
    	
 
    	
24-Aug-2005
    	
 
    
	
TW
    	
 
    	
Depomed, Inc.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Closed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
UK
    	
 
    	
Depomed, Inc.
    	
 
    	
98931204.60
    	
 
    	
05-Jun-1998
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
998271
    	
 
    	
24-Aug-2005
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
08/870509
    	
 
    	
06-Jun-1997
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
09/282233
    	
 
    	
29-Mar-1999
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6340475
    	
 
    	
22-Jan-2002
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
1870652.00
    	
 
    	
20-Nov-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
10/045823
    	
 
    	
06-Nov-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6635280
    	
 
    	
21-Oct-2003
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2364845.00
    	
 
    	
12-Dec-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2364845
    	
 
    	
20-Mar-2007
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/214264
    	
 
    	
16-Jun-2008
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
10/235076
    	
 
    	
04-Sep-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
7405238
    	
 
    	
29-Jul-2008
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
10/623481
    	
 
    	
18-Jul-2003
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/530631
    	
 
    	
22-Jun-2012
    	
 
    	
Granted
    	
 
    	
US-2012-0263792-A1
    	
 
    	
18-Oct-2012
    	
 
    	
8685450
    	
 
    	
01-Apr-2014
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
14/199972
    	
 
    	
06-Mar-2014
    	
 
    	
Allowed
    	
 
    	
US-2014-0186515-A1
    	
 
    	
03-Jul-2014
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
14/642013
    	
 
    	
09-Mar-2015
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
TW
    	
 
    	
Depomed, Inc.
    	
 
    	
93121200.00
    	
 
    	
15-Jul-2004
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2004/022554
    	
 
    	
13-Jul-2004
    	
 
    	
NAT PHASE
    	
 
    	
2005/009413
    	
 
    	
03-Feb-2005
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
NZ
    	
 
    	
Depomed, Inc.
    	
 
    	
544615.00
    	
 
    	
13-Jul-2004
    	
 
    	
Abandoned
    	
 
    	
544615
    	
 
    	
27-Feb-2009
    	
 
    	
544615
    	
 
    	
11-Jun-2009
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
PA/a/2006/00526
    	
 
    	
13-Jul-2004
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
KR
    	
 
    	
Depomed, Inc.
    	
 
    	
1020067001176.00
    	
 
    	
13-Jul-2004
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2006-520295
    	
 
    	
13-Jul-2004
    	
 
    	
Abandoned
    	
 
    	
2007-524644
    	
 
    	
30-Aug-2007
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
4778191.90
    	
 
    	
13-Jul-2004
    	
 
    	
Abandoned
    	
 
    	
1646368
    	
 
    	
19-Apr-2006
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2531721.00
    	
 
    	
06-Jan-2006
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2531721
    	
 
    	
11-Jun-2013
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
2004258903.00
    	
 
    	
13-Jul-2004
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
09/425491
    	
 
    	
22-Oct-1999
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
08/716906
    	
 
    	
19-Sep-1996
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5972389
    	
 
    	
26-Oct-1999
    	
 
    
	
UK
    	
 
    	
Depomed, Inc.
    	
 
    	
97942616.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
941071
    	
 
    	
07-Jan-2004
    	
 
    
	
CH
    	
 
    	
Depomed, Inc.
    	
 
    	
97942616.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
941071
    	
 
    	
07-Jan-2004
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
ES
    	
 
    	
Depomed, Inc.
    	
 
    	
97942616.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
941071
    	
 
    	
07-Jan-2004
    	
 
    
	
PT
    	
 
    	
Depomed, Inc.
    	
 
    	
97942616.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
941071
    	
 
    	
07-Jan-2004
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US1997/016725
    	
 
    	
18-Sep-1997
    	
 
    	
NAT PHASE
    	
 
    	
1998/11879
    	
 
    	
26-Mar-1998
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
NO
    	
 
    	
Depomed, Inc.
    	
 
    	
19991341.00
    	
 
    	
18-Sep-1997
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
NL
    	
 
    	
Depomed, Inc.
    	
 
    	
97942616.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
941071
    	
 
    	
07-Jan-2004
    	
 
    
	
KR
    	
 
    	
Depomed, Inc.
    	
 
    	
1019997002390.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
200048500
    	
 
    	
25-Jul-2000
    	
 
    	
10-0685303
    	
 
    	
14-Feb-2007
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
10514926.00
    	
 
    	
18-Sep-1997
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
IT
    	
 
    	
Depomed, Inc.
    	
 
    	
97942616.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
941071
    	
 
    	
07-Jan-2004
    	
 
    
	
IE
    	
 
    	
Depomed, Inc.
    	
 
    	
97942616.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
941071
    	
 
    	
07-Jan-2004
    	
 
    
	
DE
    	
 
    	
Depomed, Inc.
    	
 
    	
97942616.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
941071
    	
 
    	
07-Jan-2004
    	
 
    
	
FR
    	
 
    	
Depomed, Inc.
    	
 
    	
97942616.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
941071
    	
 
    	
07-Jan-2004
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
97942616.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
941071
    	
 
    	
07-Jan-2004
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
3027586.10
    	
 
    	
18-Sep-1997
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1424069
    	
 
    	
08-Sep-2004
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2266589.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2266589
    	
 
    	
03-Jan-2006
    	
 
    
	
BE
    	
 
    	
Depomed, Inc.
    	
 
    	
97942616.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
941071
    	
 
    	
07-Jan-2004
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
4428097.00
    	
 
    	
18-Sep-1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
741760
    	
 
    	
21-Mar-2002
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
09/498945
    	
 
    	
04-Feb-2000
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/770283
    	
 
    	
29-Apr-2010
    	
 
    	
Granted
    	
 
    	
US-2010-0272808-A1
    	
 
    	
28-Oct-2010
    	
 
    	
8043630
    	
 
    	
25-Oct-2011
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/156225
    	
 
    	
08-Jun-2011
    	
 
    	
Granted
    	
 
    	
US-2011-0236485-A1
    	
 
    	
29-Sep-2011
    	
 
    	
8329215
    	
 
    	
11-Dec-2012
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/688114
    	
 
    	
28-Nov-2012
    	
 
    	
Granted
    	
 
    	
US 2013-0164377 A1
    	
 
    	
27-Jun-2013
    	
 
    	
8945619
    	
 
    	
03-Feb-2015
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
10/213823
    	
 
    	
07-Aug-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
7736667
    	
 
    	
15-Jun-2010
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
14/584805
    	
 
    	
29-Dec-2014
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
UK
    	
 
    	
Depomed, Inc.
    	
 
    	
1906794.10
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1251832
    	
 
    	
27-Sep-2006
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
3466101.00
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
767812
    	
 
    	
11-Mar-2004
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
BE
    	
 
    	
Depomed, Inc.
    	
 
    	
1906794.10
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1251832
    	
 
    	
27-Sep-2006
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2396782.00
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
1906794.10
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1251832
    	
 
    	
27-Sep-2006
    	
 
    
	
FR
    	
 
    	
Depomed, Inc.
    	
 
    	
1906794.10
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1251832
    	
 
    	
27-Sep-2006
    	
 
    
	
DE
    	
 
    	
Depomed, Inc.
    	
 
    	
1906794.10
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1251832
    	
 
    	
27-Sep-2006
    	
 
    
	
HK
    	
 
    	
Depomed, Inc.
    	
 
    	
3102713.90
    	
 
    	
15-Apr-2003
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1050493
    	
 
    	
01-Dec-2006
    	
 
    
	
IE
    	
 
    	
Depomed, Inc.
    	
 
    	
1906794.10
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1251832
    	
 
    	
27-Sep-2006
    	
 
    
	
IL
    	
 
    	
Depomed, Inc.
    	
 
    	
150568.00
    	
 
    	
30-Jan-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
150568
    	
 
    	
04-Mar-2008
    	
 
    
	
IT
    	
 
    	
Depomed, Inc.
    	
 
    	
1906794.10
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1251832
    	
 
    	
27-Sep-2006
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2001556236.00
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
PA/a/2002/007254
    	
 
    	
30-Jan-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
241836
    	
 
    	
08-Nov-2006
    	
 
    
	
NL
    	
 
    	
Depomed, Inc.
    	
 
    	
1906794.10
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1251832
    	
 
    	
27-Sep-2006
    	
 
    
	
NZ
    	
 
    	
Depomed, Inc.
    	
 
    	
519921.00
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
519921
    	
 
    	
29-Mar-2004
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2001/003027
    	
 
    	
30-Jan-2001
    	
 
    	
NAT PHASE
    	
 
    	
2001/056544
    	
 
    	
09-Aug-2001
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PT
    	
 
    	
Depomed, Inc.
    	
 
    	
1906794.10
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1251832
    	
 
    	
27-Sep-2006
    	
 
    
	
ES
    	
 
    	
Depomed, Inc.
    	
 
    	
1906794.10
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1251832
    	
 
    	
27-Sep-2006
    	
 
    
	
SE
    	
 
    	
Depomed, Inc.
    	
 
    	
1906794.10
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1251832
    	
 
    	
27-Sep-2006
    	
 
    
	
CH
    	
 
    	
Depomed, Inc.
    	
 
    	
1906794.10
    	
 
    	
30-Jan-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1251832
    	
 
    	
27-Sep-2006
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
2001239893.00
    	
 
    	
26-Feb-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2001239893
    	
 
    	
03-Mar-2005
    	
 
    
	
BE
    	
 
    	
Depomed, Inc.
    	
 
    	
1914515.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1294363
    	
 
    	
17-Dec-2003
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2412671.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2412671
    	
 
    	
03-Oct-2006
    	
 
    
	
DK
    	
 
    	
Depomed, Inc.
    	
 
    	
1914515.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1294363
    	
 
    	
17-Dec-2003
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
1914515.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1294363
    	
 
    	
17-Dec-2003
    	
 
    
	
FR
    	
 
    	
Depomed, Inc.
    	
 
    	
1914515.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1294363
    	
 
    	
17-Dec-2003
    	
 
    
	
DE
    	
 
    	
Depomed, Inc.
    	
 
    	
1914515.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1294363
    	
 
    	
17-Dec-2003
    	
 
    
	
IE
    	
 
    	
Depomed, Inc.
    	
 
    	
1914515.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1294363
    	
 
    	
17-Dec-2003
    	
 
    
	
IL
    	
 
    	
Depomed, Inc.
    	
 
    	
153464.00
    	
 
    	
26-Feb-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
IT
    	
 
    	
Depomed, Inc.
    	
 
    	
1914515.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1294363
    	
 
    	
17-Dec-2003
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2002-503260
    	
 
    	
20-Dec-2002
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2008-213240
    	
 
    	
26-Feb-2001
    	
 
    	
Abandoned
    	
 
    	
2009-040787
    	
 
    	
26-Feb-2009
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2013-142872
    	
 
    	
08-Jul-2013
    	
 
    	
Pending
    	
 
    	
2013-224324
    	
 
    	
31-Oct-2013
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
KR
    	
 
    	
Depomed, Inc.
    	
 
    	
10-2002-7017415
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10-0716756
    	
 
    	
14-May-2007
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
PA/a/2002/012614
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
245737
    	
 
    	
09-May-2007
    	
 
    
	
NL
    	
 
    	
Depomed, Inc.
    	
 
    	
1914515.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1294363
    	
 
    	
17-Dec-2003
    	
 
    
	
NZ
    	
 
    	
Depomed, Inc.
    	
 
    	
523214.00
    	
 
    	
26-Feb-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
523214
    	
 
    	
08-Dec-2003
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2001/006164
    	
 
    	
26-Feb-2001
    	
 
    	
NAT PHASE
    	
 
    	
2001/97783
    	
 
    	
27-Dec-2001
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PT
    	
 
    	
Depomed, Inc.
    	
 
    	
1914515.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1294363
    	
 
    	
17-Dec-2003
    	
 
    
	
ES
    	
 
    	
Depomed, Inc.
    	
 
    	
1914515.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1294363
    	
 
    	
17-Dec-2003
    	
 
    
	
SE
    	
 
    	
Depomed, Inc.
    	
 
    	
1914515.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1294363
    	
 
    	
17-Dec-2003
    	
 
    
	
CH
    	
 
    	
Depomed, Inc.
    	
 
    	
1914515.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1294363
    	
 
    	
17-Dec-2003
    	
 
    
	
UK
    	
 
    	
Depomed, Inc.
    	
 
    	
1914515.00
    	
 
    	
26-Feb-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1294363
    	
 
    	
17-Dec-2003
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
2314787.00
    	
 
    	
20-Jun-2000
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6488962
    	
 
    	
03-Dec-2002
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
2002211923.00
    	
 
    	
16-Oct-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2002211923
    	
 
    	
16-Mar-2006
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2422711.00
    	
 
    	
16-Oct-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2422711
    	
 
    	
07-Jul-2009
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
1980020.00
    	
 
    	
16-Oct-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1326643
    	
 
    	
28-Dec-2005
    	
 
    
	
FR
    	
 
    	
Depomed, Inc.
    	
 
    	
1980020.00
    	
 
    	
16-Oct-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1326643
    	
 
    	
28-Dec-2005
    	
 
    
	
DE
    	
 
    	
Depomed, Inc.
    	
 
    	
1980020.00
    	
 
    	
16-Oct-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
60116353.2
    	
 
    	
28-Dec-2005
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
IL
    	
 
    	
Depomed, Inc.
    	
 
    	
154988.00
    	
 
    	
16-Oct-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
IT
    	
 
    	
Depomed, Inc.
    	
 
    	
1980020.00
    	
 
    	
16-Oct-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1326643
    	
 
    	
28-Dec-2005
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2002535654.00
    	
 
    	
16-Oct-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
KR
    	
 
    	
Depomed, Inc.
    	
 
    	
1020037005263.00
    	
 
    	
16-Oct-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10-0907640
    	
 
    	
14-Jul-2009
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
PA/a/2003/003128
    	
 
    	
16-Oct-2001
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
232349
    	
 
    	
23-Nov-2005
    	
 
    
	
NZ
    	
 
    	
Depomed, Inc.
    	
 
    	
524790.00
    	
 
    	
16-Oct-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
524790
    	
 
    	
06-Mar-2006
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2001/042751
    	
 
    	
16-Oct-2001
    	
 
    	
NAT PHASE
    	
 
    	
2002/032416
    	
 
    	
25-Apr-2002
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PT
    	
 
    	
Depomed, Inc.
    	
 
    	
1980020.00
    	
 
    	
16-Oct-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1326643
    	
 
    	
28-Dec-2005
    	
 
    
	
ES
    	
 
    	
Depomed, Inc.
    	
 
    	
1980020.00
    	
 
    	
16-Oct-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1326643
    	
 
    	
28-Dec-2005
    	
 
    
	
CH
    	
 
    	
Depomed, Inc.
    	
 
    	
1980020.00
    	
 
    	
16-Oct-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1326643
    	
 
    	
28-Dec-2005
    	
 
    
	
UK
    	
 
    	
Depomed, Inc.
    	
 
    	
1980020.00
    	
 
    	
16-Oct-2001
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1326643
    	
 
    	
28-Dec-2005
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
09/691398
    	
 
    	
17-Oct-2000
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6451808
    	
 
    	
17-Sep-2002
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
2002337974.00
    	
 
    	
22-Oct-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2002337974
    	
 
    	
01-Jun-2006
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2409999.00
    	
 
    	
24-Oct-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2409999
    	
 
    	
04-Sep-2007
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
2773879.80
    	
 
    	
22-Oct-2002
    	
 
    	
Granted
    	
 
    	
1446106
    	
 
    	
18-Aug-2004
    	
 
    	
1446106
    	
 
    	
14-Dec-2011
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
10178869.30
    	
 
    	
22-Oct-2002
    	
 
    	
Abandoned
    	
 
    	
2260832
    	
 
    	
15-Dec-2010
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
FR
    	
 
    	
Depomed, Inc.
    	
 
    	
2773879.80
    	
 
    	
22-Oct-2002
    	
 
    	
Granted
    	
 
    	
1446106
    	
 
    	
18-Aug-2004
    	
 
    	
1446106
    	
 
    	
14-Dec-2011
    	
 
    
	
DE
    	
 
    	
Depomed, Inc.
    	
 
    	
2773879.80
    	
 
    	
22-Oct-2002
    	
 
    	
Granted
    	
 
    	
1446106
    	
 
    	
18-Aug-2004
    	
 
    	
1446106
    	
 
    	
14-Dec-2011
    	
 
    
	
IE
    	
 
    	
Depomed, Inc.
    	
 
    	
2773879.80
    	
 
    	
22-Oct-2002
    	
 
    	
Granted
    	
 
    	
1446106
    	
 
    	
18-Aug-2004
    	
 
    	
1446106
    	
 
    	
14-Dec-2011
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2003-537738
    	
 
    	
22-Oct-2002
    	
 
    	
Granted
    	
 
    	
2005-532985
    	
 
    	
04-Nov-2005
    	
 
    	
5133495
    	
 
    	
16-Nov-2012
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2012-196459
    	
 
    	
06-Sep-2012
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
LU
    	
 
    	
Depomed, Inc.
    	
 
    	
2773879.80
    	
 
    	
22-Oct-2002
    	
 
    	
Granted
    	
 
    	
1446106
    	
 
    	
18-Aug-2004
    	
 
    	
1446106
    	
 
    	
14-Dec-2011
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
PA/a/2004/003793
    	
 
    	
22-Oct-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
241834
    	
 
    	
08-Nov-2006
    	
 
    
	
MC
    	
 
    	
Depomed, Inc.
    	
 
    	
2773879.80
    	
 
    	
22-Oct-2002
    	
 
    	
Granted
    	
 
    	
1446106
    	
 
    	
18-Aug-2004
    	
 
    	
1446106
    	
 
    	
14-Dec-2011
    	
 
    
	
NZ
    	
 
    	
Depomed, Inc.
    	
 
    	
532536.00
    	
 
    	
22-Oct-2002
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2002/033968
    	
 
    	
22-Oct-2002
    	
 
    	
NAT PHASE
    	
 
    	
2003/035177
    	
 
    	
01-May-2003
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CH
    	
 
    	
Depomed, Inc.
    	
 
    	
2773879.80
    	
 
    	
22-Oct-2002
    	
 
    	
Granted
    	
 
    	
1446106
    	
 
    	
18-Aug-2004
    	
 
    	
1446106
    	
 
    	
14-Dec-2011
    	
 
    
	
TW
    	
 
    	
Depomed, Inc.
    	
 
    	
91124778.00
    	
 
    	
24-Oct-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
I325326
    	
 
    	
01-Jun-2010
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
UK
    	
 
    	
Depomed, Inc.
    	
 
    	
2773879.80
    	
 
    	
22-Oct-2002
    	
 
    	
Granted
    	
 
    	
1446106
    	
 
    	
18-Aug-2004
    	
 
    	
1446106
    	
 
    	
14-Dec-2011
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Closed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
10/029134
    	
 
    	
25-Oct-2001
    	
 
    	
Granted
    	
 
    	
US2003-0104053A1
    	
 
    	
05-Jun-2003
    	
 
    	
6723340
    	
 
    	
20-Apr-2004
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
2003207755.00
    	
 
    	
28-Jan-2003
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2003207755
    	
 
    	
25-Jan-2007
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2417686.00
    	
 
    	
28-Jan-2003
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2417686
    	
 
    	
06-Jun-2006
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
3705993.80
    	
 
    	
28-Jan-2003
    	
 
    	
Abandoned
    	
 
    	
1469838
    	
 
    	
27-Oct-2004
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
HK
    	
 
    	
Depomed, Inc.
    	
 
    	
4110096.80
    	
 
    	
21-Dec-2004
    	
 
    	
Abandoned
    	
 
    	
1067050A
    	
 
    	
01-Apr-2005
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
IL
    	
 
    	
Depomed, Inc.
    	
 
    	
163205.00
    	
 
    	
28-Jan-2003
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
163205
    	
 
    	
21-Oct-2009
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2003565452.00
    	
 
    	
28-Jan-2003
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
KR
    	
 
    	
Depomed, Inc.
    	
 
    	
10-2004-7011934
    	
 
    	
28-Jan-2003
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10-0680574
    	
 
    	
02-Feb-2007
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
PA/a/2004/007371
    	
 
    	
28-Jan-2003
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
243248
    	
 
    	
10-Jan-2007
    	
 
    
	
NZ
    	
 
    	
Depomed, Inc.
    	
 
    	
534312.00
    	
 
    	
28-Jan-2003
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
534312
    	
 
    	
08-Jun-2006
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2003/002809
    	
 
    	
28-Jan-2003
    	
 
    	
NAT PHASE
    	
 
    	
2003/066028
    	
 
    	
29-Aug-2003
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
TW
    	
 
    	
Depomed, Inc.
    	
 
    	
92102293.00
    	
 
    	
20-Jan-2003
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
I280141
    	
 
    	
01-May-2007
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
-470888.00
    	
 
    	
01-Feb-2002
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6682759
    	
 
    	
27-Jan-2004
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
2009223061.00
    	
 
    	
11-Mar-2009
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2009223061
    	
 
    	
22-Jan-2015
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2720108.00
    	
 
    	
30-Sep-2010
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CN
    	
 
    	
Depomed, Inc.
    	
 
    	
200980116247.70
    	
 
    	
05-Nov-2010
    	
 
    	
Granted
    	
 
    	
102105136
    	
 
    	
22-Jun-2011
    	
 
    	
ZL200980116247.7
    	
 
    	
26-Nov-2014
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
9720928.20
    	
 
    	
11-Mar-2009
    	
 
    	
Granted
    	
 
    	
2262484
    	
 
    	
22-Dec-2010
    	
 
    	
2262484
    	
 
    	
23-Jan-2013
    	
 
    
	
FR
    	
 
    	
Depomed, Inc.
    	
 
    	
9720928.20
    	
 
    	
11-Mar-2009
    	
 
    	
Granted
    	
 
    	
2262484
    	
 
    	
22-Dec-2010
    	
 
    	
2262484
    	
 
    	
23-Jan-2013
    	
 
    
	
DE
    	
 
    	
Depomed, Inc.
    	
 
    	
9720928.20
    	
 
    	
11-Mar-2009
    	
 
    	
Granted
    	
 
    	
2262484
    	
 
    	
22-Dec-2010
    	
 
    	
2262484
    	
 
    	
23-Jan-2013
    	
 
    
	
HK
    	
 
    	
Depomed, Inc.
    	
 
    	
11105856.90
    	
 
    	
09-Jun-2011
    	
 
    	
Granted
    	
 
    	
1152469A
    	
 
    	
02-Mar-2012
    	
 
    	
HK1152469
    	
 
    	
19-Sep-2013
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2010-550846
    	
 
    	
11-Mar-2009
    	
 
    	
Granted
    	
 
    	
2011-513499
    	
 
    	
28-Apr-2011
    	
 
    	
5607550
    	
 
    	
05-Sep-2014
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
MX/a/2010/009990
    	
 
    	
11-Mar-2009
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
306299
    	
 
    	
18-Dec-2012
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2009/036864
    	
 
    	
11-Mar-2009
    	
 
    	
NAT PHASE
    	
 
    	
WO 2009/114648
    	
 
    	
17-Sep-2009
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
UK
    	
 
    	
Depomed, Inc.
    	
 
    	
9720928.20
    	
 
    	
11-Mar-2009
    	
 
    	
Granted
    	
 
    	
2262484
    	
 
    	
22-Dec-2010
    	
 
    	
2262484
    	
 
    	
23-Jan-2013
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
61/035696
    	
 
    	
11-Mar-2008
    	
 
    	
Completed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
2688887.00
    	
 
    	
11-Mar-2009
    	
 
    	
Granted
    	
 
    	
US-2010-0015222-A1
    	
 
    	
21-Jan-2010
    	
 
    	
8377453
    	
 
    	
19-Feb-2013
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/644444
    	
 
    	
22-Dec-2009
    	
 
    	
Granted
    	
 
    	
US-2010-0196474-A1
    	
 
    	
05-Aug-2010
    	
 
    	
8372432
    	
 
    	
12-Feb-2013
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/360595
    	
 
    	
27-Jan-2012
    	
 
    	
Granted
    	
 
    	
US2012-0136022A1
    	
 
    	
31-May-2012
    	
 
    	
8394408
    	
 
    	
12-Mar-2013
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/529960
    	
 
    	
21-Jun-2012
    	
 
    	
Granted
    	
 
    	
US-2012-0321713-A1
    	
 
    	
20-Dec-2012
    	
 
    	
8668929
    	
 
    	
11-Mar-2014
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Closed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
14/196143
    	
 
    	
04-Mar-2014
    	
 
    	
Pending
    	
 
    	
US-2014-0186440-A1
    	
 
    	
03-Jul-2014
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
2009281752.00
    	
 
    	
14-Aug-2009
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
BR
    	
 
    	
Depomed, Inc.
    	
 
    	
14671.00
    	
 
    	
15-Feb-2011
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2733787.00
    	
 
    	
10-Feb-2011
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CN
    	
 
    	
Depomed, Inc.
    	
 
    	
200980141342.20
    	
 
    	
14-Aug-2011
    	
 
    	
Pending
    	
 
    	
102202656
    	
 
    	
28-Sep-2011
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
9791546.60
    	
 
    	
10-Mar-2011
    	
 
    	
Pending
    	
 
    	
2326310
    	
 
    	
01-Jun-2011
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
HK
    	
 
    	
Depomed, Inc.
    	
 
    	
11112402.40
    	
 
    	
17-Nov-2011
    	
 
    	
Pending
    	
 
    	
1158064A
    	
 
    	
13-Jul-2012
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
2011-523207
    	
 
    	
15-Feb-2011
    	
 
    	
Abandoned
    	
 
    	
2012-500221
    	
 
    	
05-Jan-2012
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
KR
    	
 
    	
Depomed, Inc.
    	
 
    	
10-2011-7005446
    	
 
    	
08-Mar-2011
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
MX/a/2011/001639
    	
 
    	
11-Feb-2011
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2009/053937
    	
 
    	
14-Aug-2009
    	
 
    	
NAT PHASE
    	
 
    	
WO 2010/019915
    	
 
    	
18-Feb-2010
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
61/089339
    	
 
    	
15-Aug-2008
    	
 
    	
Completed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
61/122276
    	
 
    	
12-Dec-2008
    	
 
    	
Completed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/541836
    	
 
    	
14-Aug-2009
    	
 
    	
Pending
    	
 
    	
US-2010-0040689-A1
    	
 
    	
18-Feb-2010
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
 
    	
 
    	
10-Feb-2009
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
 
    	
 
    	
10-Feb-2009
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CN
    	
 
    	
Depomed, Inc.
    	
 
    	
 
    	
 
    	
10-Feb-2009
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
9709706.70
    	
 
    	
10-Feb-2009
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
IL
    	
 
    	
Depomed, Inc.
    	
 
    	
207508.00
    	
 
    	
10-Feb-2009
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
JP
    	
 
    	
Depomed, Inc.
    	
 
    	
 
    	
 
    	
10-Feb-2009
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
KR
    	
 
    	
Depomed, Inc.
    	
 
    	
 
    	
 
    	
10-Feb-2009
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
 
    	
 
    	
10-Feb-2009
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
NZ
    	
 
    	
Depomed, Inc.
    	
 
    	
 
    	
 
    	
10-Feb-2009
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2009/033702
    	
 
    	
10-Feb-2009
    	
 
    	
NAT PHASE
    	
 
    	
WO 2009/102734
    	
 
    	
20-Aug-2009
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/368907
    	
 
    	
10-Feb-2009
    	
 
    	
Granted
    	
 
    	
US-2009-0209645-A1
    	
 
    	
20-Aug-2009
    	
 
    	
8329750
    	
 
    	
11-Dec-2012
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/686865
    	
 
    	
27-Nov-2012
    	
 
    	
Abandoned
    	
 
    	
US-2013-0158121-A1
    	
 
    	
20-Jun-2013
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
AU
    	
 
    	
Depomed, Inc.
    	
 
    	
2010286354.00
    	
 
    	
31-Aug-2010
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
BR
    	
 
    	
Depomed, Inc.
    	
 
    	
1120120045253.00
    	
 
    	
31-Aug-2010
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CN
    	
 
    	
Depomed, Inc.
    	
 
    	
201080049502.30
    	
 
    	
31-Aug-2010
    	
 
    	
Abandoned
    	
 
    	
102596252
    	
 
    	
18-Jul-2012
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
10812767.10
    	
 
    	
31-Aug-2010
    	
 
    	
Abandoned
    	
 
    	
2473195
    	
 
    	
11-Jul-2012
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
IN
    	
 
    	
Depomed, Inc.
    	
 
    	
2748/CHENP/2012
    	
 
    	
31-Aug-2010
    	
 
    	
Pending
    	
 
    	
2748/CHENP/2012 A
    	
 
    	
10-May-2013
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
IL
    	
 
    	
Depomed, Inc.
    	
 
    	
218370.00
    	
 
    	
28-Feb-2012
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
KR
    	
 
    	
Depomed, Inc.
    	
 
    	
10-2012-7007703
    	
 
    	
26-Mar-2012
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
NZ
    	
 
    	
Depomed, Inc.
    	
 
    	
598922.00
    	
 
    	
21-Mar-2012
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
598922
    	
 
    	
01-Jul-2014
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2010/047369
    	
 
    	
31-Aug-2010
    	
 
    	
NAT PHASE
    	
 
    	
WO 2011/026125
    	
 
    	
03-Mar-2011
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PL
    	
 
    	
Depomed, Inc.
    	
 
    	
P.399450
    	
 
    	
29-Feb-2012
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
RU
    	
 
    	
Depomed, Inc.
    	
 
    	
2012112552.00
    	
 
    	
30-Mar-2012
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
10-Oct-2013
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
ZA
    	
 
    	
Depomed, Inc.
    	
 
    	
2012/02061
    	
 
    	
31-Aug-2010
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2012/02061
    	
 
    	
29-May-2013
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
61/238374
    	
 
    	
31-Aug-2009
    	
 
    	
Completed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/872723
    	
 
    	
31-Aug-2010
    	
 
    	
Pending
    	
 
    	
US-2011-0052685-A1
    	
 
    	
03-Mar-2011
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2783342.00
    	
 
    	
07-Jun-2012
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
10836650.10
    	
 
    	
08-Dec-2010
    	
 
    	
Abandoned
    	
 
    	
2509635
    	
 
    	
17-Oct-2012
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2010/059561
    	
 
    	
08-Dec-2010
    	
 
    	
NAT PHASE
    	
 
    	
WO 2011/072069
    	
 
    	
16-Jun-2011
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/963520
    	
 
    	
08-Dec-2010
    	
 
    	
Abandoned
    	
 
    	
US2011-0135728A1
    	
 
    	
09-Jun-2011
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
61/267669
    	
 
    	
08-Dec-2009
    	
 
    	
Completed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
CA
    	
 
    	
Depomed, Inc.
    	
 
    	
2850468.00
    	
 
    	
28-Mar-2014
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
EPO
    	
 
    	
Depomed, Inc.
    	
 
    	
11833073.70
    	
 
    	
25-Apr-2013
    	
 
    	
Pending
    	
 
    	
2621487
    	
 
    	
07-Aug-2013
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
MX
    	
 
    	
Depomed, Inc.
    	
 
    	
MX/a/2013/003556
    	
 
    	
28-Sep-2011
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/US2011/053769
    	
 
    	
28-Sep-2011
    	
 
    	
NAT PHASE
    	
 
    	
WO 2012/050922
    	
 
    	
19-Apr-2012
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/247956
    	
 
    	
28-Sep-2011
    	
 
    	
Allowed
    	
 
    	
US-2012-0077878-A1
    	
 
    	
29-Mar-2012
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
14/632959
    	
 
    	
26-Feb-2015
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/622511
    	
 
    	
19-Sep-2012
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
14/340499
    	
 
    	
24-Jul-2014
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
61/650451
    	
 
    	
22-May-2012
    	
 
    	
Completed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/900312
    	
 
    	
22-May-2013
    	
 
    	
Pending
    	
 
    	
US 2013-0316002-A1
    	
 
    	
28-Nov-2013
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
60/071865
    	
 
    	
20-Jan-1998
    	
 
    	
Completed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
09/232354
    	
 
    	
15-Jan-1999
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6287594
    	
 
    	
11-Sep-2001
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
09/354982
    	
 
    	
16-Jul-1999
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6365180
    	
 
    	
02-Apr-2002
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
61/055581
    	
 
    	
23-May-2008
    	
 
    	
Completed
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/391,434
    	
 
    	
24-Feb-2009
    	
 
    	
Granted
    	
 
    	
US2009-0292022A1
    	
 
    	
26-Nov-2009
    	
 
    	
7662858
    	
 
    	
16-Feb-2010
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
2132987.00
    	
 
    	
15-May-2009
    	
 
    	
Granted
    	
 
    	
US-2009-0292023-A1
    	
 
    	
26-Nov-2009
    	
 
    	
7939518
    	
 
    	
10-May-2011
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/706117
    	
 
    	
16-Feb-2010
    	
 
    	
Granted
    	
 
    	
US-2010-0144882-A1
    	
 
    	
10-Jun-2010
    	
 
    	
8110606
    	
 
    	
07-Feb-2012
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/772858
    	
 
    	
03-May-2010
    	
 
    	
Granted
    	
 
    	
US-2010-0222430-A1
    	
 
    	
02-Sep-2010
    	
 
    	
7884095
    	
 
    	
08-Feb-2011
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/205033
    	
 
    	
08-Aug-2011
    	
 
    	
Granted
    	
 
    	
US-2011-0300207-A1
    	
 
    	
08-Dec-2011
    	
 
    	
8623920
    	
 
    	
07-Jan-2014
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
14/137605
    	
 
    	
20-Dec-2013
    	
 
    	
Pending
    	
 
    	
US-2014-0107210-A1
    	
 
    	
17-Apr-2014
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
PCT
    	
 
    	
Depomed, Inc.
    	
 
    	
PCT/GB1998/001147
    	
 
    	
20-Apr-1998
    	
 
    	
NAT PHASE
    	
 
    	
WO/1998/047535
    	
 
    	
29-Oct-1998
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
2871052.00
    	
 
    	
20-Jan-2000
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6432440
    	
 
    	
13-Aug-2002
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
30225.00
    	
 
    	
15-Jul-2002
    	
 
    	
Abandoned
    	
 
    	
US 2002-0197324 A1
    	
 
    	
26-Dec-2002
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
11/562002
    	
 
    	
21-Nov-2006
    	
 
    	
Abandoned
    	
 
    	
US 2007-0110677 A1
    	
 
    	
17-May-2007
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
11/562173
    	
 
    	
21-Nov-2006
    	
 
    	
Abandoned
    	
 
    	
US 2007-0092535 A1
    	
 
    	
26-Apr-2007
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/078575
    	
 
    	
01-Apr-2011
    	
 
    	
Abandoned
    	
 
    	
US 2011-0182857 A1
    	
 
    	
28-Jul-2011
    	
 
    	
 
    	
 
    	
 
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
10/753628
    	
 
    	
08-Jan-2004
    	
 
    	
Abandoned
    	
 
    	
US 2004-0166067 A1
    	
 
    	
26-Aug-2004
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
12/047388
    	
 
    	
13-Mar-2008
    	
 
    	
Granted
    	
 
    	
US 2008-0153879 A1
    	
 
    	
26-Jun-2008
    	
 
    	
8216604
    	
 
    	
10-Jul-2012
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/541314
    	
 
    	
03-Jul-2012
    	
 
    	
Granted
    	
 
    	
US 2012-0277267 A1
    	
 
    	
01-Nov-2012
    	
 
    	
8889176
    	
 
    	
18-Nov-2014
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
13/541325
    	
 
    	
03-Jul-2012
    	
 
    	
Pending
    	
 
    	
US 2012-0270903 A1
    	
 
    	
25-Oct-2012
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
62/063311
    	
 
    	
13-Oct-2014
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
62/092487
    	
 
    	
16-Dec-2014
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
08/453144
    	
 
    	
30-May-1995
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5582837
    	
 
    	
10-Dec-1996
    	
 
    
	
US
    	
 
    	
Depomed, Inc.
    	
 
    	
14/012,484
    	
 
    	
28-Aug-2013
    	
 
    	
Pending
    	
 
    	
2014-0066411
    	
 
    	
6-Mar-2014
    	
 
    	
 
    	
 
    	
 
    	
 
    


 

LICENSED PATENTS

 

Depomed, Inc.

 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
US
    	
 
    	
Archemides Development   Limited
    	
 
    	
13/122332
    	
 
    	
6/27/2011
    	
 
    	
Pending
    	
 
    	
2011/0257632
    	
 
    	
10/20/2011
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Archemides Development   Limited
    	
 
    	
13/147,746
    	
 
    	
2/4/2010
    	
 
    	
Granted
    	
 
    	
2012/0055929
    	
 
    	
3/8/2012
    	
 
    	
8915393
    	
 
    	
12/23/2014
    	
 
    
	
US
    	
 
    	
Archemides Development Limited
    	
 
    	
29/352864
    	
 
    	
12/29/2009
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
D663943
    	
 
    	
7/24/2012
    	
 
    
	
CA
    	
 
    	
Archemides Development   Limited
    	
 
    	
133458
    	
 
    	
12/23/2009
    	
 
    	
Granted
    	
 
    	
133458
    	
 
    	
 
    	
 
    	
133458
    	
 
    	
7/29/2010
    	
 
    
	
US
    	
 
    	
Archemides Development   Limited
    	
 
    	
13/196061
    	
 
    	
2/2/2012
    	
 
    	
Pending
    	
 
    	
2012/0024724
    	
 
    	
2/2/2012
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Archemides Development   Limited
    	
 
    	
13/983,400
    	
 
    	
1/26/2012
    	
 
    	
Pending
    	
 
    	
2013/0313287
    	
 
    	
11/28/2013
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CA
    	
 
    	
Archemides Development   Limited
    	
 
    	
2824385
    	
 
    	
1/26/2012
    	
 
    	
Pending
    	
 
    	
2824385
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CA
    	
 
    	
Archemides Development   Limited
    	
 
    	
141646
    	
 
    	
8/3/2011
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
141646
    	
 
    	
4/26/2012
    	
 
    
	
US
    	
 
    	
Takeda Pharma A/S
    	
 
    	
10/343449
    	
 
    	
7/31/2001
    	
 
    	
Granted
    	
 
    	
2004/0034059
    	
 
    	
3/19/2004
    	
 
    	
8017627
    	
 
    	
9/13/2011
    	
 
    
	
US
    	
 
    	
Takeda Pharma A/S
    	
 
    	
11/656970
    	
 
    	
1/24/2007
    	
 
    	
Granted
    	
 
    	
2007/0134164
    	
 
    	
6/14/2007
    	
 
    	
8158651
    	
 
    	
4/17/2012
    	
 
    
	
US
    	
 
    	
Takeda Pharma A/S
    	
 
    	
13/188862
    	
 
    	
1/22/2011
    	
 
    	
Granted
    	
 
    	
2011/0291914
    	
 
    	
11/17/2011
    	
 
    	
8653107
    	
 
    	
2/18/2014
    	
 
    
	
CA
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
2417737
    	
 
    	
7/13/2004
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2417727
    	
 
    	
9/1/2009
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
09/192493
    	
 
    	
11/17/1995
    	
 
    	
Abandoned
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
09/524,747
    	
 
    	
3/14/2000
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6794595
    	
 
    	
12/13/2005
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
11/030537
    	
 
    	
1/5/2005
    	
 
    	
Abandoned
    	
 
    	
2005/0147671
    	
 
    	
7/7/2005
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
13/481478
    	
 
    	
5/25/2012
    	
 
    	
Pending
    	
 
    	
2013/0142874
    	
 
    	
6/6/2013
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
11/132023
    	
 
    	
5/18/2005
    	
 
    	
Abandoned
    	
 
    	
2005/0215643
    	
 
    	
9/29/2005
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
11/132024
    	
 
    	
5/18/2005
    	
 
    	
Granted
    	
 
    	
2005/0214363
    	
 
    	
9/29/2005
    	
 
    	
7482377
    	
 
    	
1/27/2006
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
11/180996
    	
 
    	
7/13/2005
    	
 
    	
Abandoned
    	
 
    	
2006/0013896
    	
 
    	
1/19/2006
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
11/351611
    	
 
    	
2/10/2006
    	
 
    	
Granted
    	
 
    	
2006/0188565
    	
 
    	
8/24/2006
    	
 
    	
7687542
    	
 
    	
3/30/2010
    	
 
    
	
CA
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
2254144
    	
 
    	
5/15/1997
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2254144
    	
 
    	
11/20/2007
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
11/455120
    	
 
    	
6/16/2006
    	
 
    	
Granted
    	
 
    	
2007/0015831
    	
 
    	
1/18/2007
    	
 
    	
7759394
    	
 
    	
7/20/2010
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
12/399175
    	
 
    	
3/6/2009
    	
 
    	
Abandoned
    	
 
    	
2009/0197961
    	
 
    	
8/6/2009
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
12/683517
    	
 
    	
1/7/2010
    	
 
    	
Granted
    	
 
    	
2010/0204330
    	
 
    	
8/12/2010
    	
 
    	
8097651
    	
 
    	
1/17/2012
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
13/742871
    	
 
    	
1/16/2013
    	
 
    	
Granted
    	
 
    	
2013/0245122
    	
 
    	
9/19/2013
    	
 
    	
8927604
    	
 
    	
1/6/2015
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
14/534428
    	
 
    	
11/6/2014
    	
 
    	
Published
    	
 
    	
2015/0064258
    	
 
    	
3/5/2015
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CA
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
2632375
    	
 
    	
6/16/2006
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
11/348634
    	
 
    	
2/7/2006
    	
 
    	
Granted
    	
 
    	
2007/0184106
    	
 
    	
8/9/2007
    	
 
    	
7939561
    	
 
    	
5/10/2011
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
60/795,214
    	
 
    	
4/25/2006
    	
 
    	
Expired
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
12/298550
    	
 
    	
4/1/2009
    	
 
    	
Abandoned
    	
 
    	
2010/0016363
    	
 
    	
1/21/2010
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
CA
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
2661819
    	
 
    	
4/25/2007
    	
 
    	
Granted
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2661819
    	
 
    	
7/29/2014
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
11/349008
    	
 
    	
2/7/2006
    	
 
    	
Granted
    	
 
    	
2007/0184107
    	
 
    	
8/9/2007
    	
 
    	
7700125
    	
 
    	
4/20/2010
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
12/555975
    	
 
    	
9/9/2009
    	
 
    	
Granted
    	
 
    	
2011/0105613
    	
 
    	
5/5/2011
    	
 
    	
8097267
    	
 
    	
1/17/2012
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
13/331324
    	
 
    	
12/20/2011
    	
 
    	
Abandoned
    	
 
    	
2012/0208886
    	
 
    	
8/16/2012
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
APR Applied Pharma   Research SA
    	
 
    	
13/769508
    	
 
    	
2/18/2013
    	
 
    	
Abandoned
    	
 
    	
2013/0267602
    	
 
    	
10/10/2013
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Valeant International
    	
 
    	
14/262622
    	
 
    	
25-Apr-2014
    	
 
    	
Published
    	
 
    	
20150030675
    	
 
    	
29-Jan-2015
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
09/838,192
    	
 
    	
06 Jun 1995
    	
 
    	
 
    	
 
    	
20020010178
    	
 
    	
 
    	
 
    	
6344558
    	
 
    	
05 Feb 2002
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
08/466,911
    	
 
    	
06 Jun 1995
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6248737
    	
 
    	
19 Jun 2001
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
10/462,844
    	
 
    	
17 Jun 2003
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
RE39593
    	
 
    	
19 Jun 2001
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/868,635
    	
 
    	
22 Oct 2002
    	
 
    	
 
    	
 
    	
20130237608
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/850,208
    	
 
    	
11 Mar 2008
    	
 
    	
 
    	
 
    	
20100311842
    	
 
    	
 
    	
 
    	
8536130
    	
 
    	
17 Sep 2013
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/634,777
    	
 
    	
27 Jun 2005
    	
 
    	
 
    	
 
    	
20100160447
    	
 
    	
 
    	
 
    	
7994364
    	
 
    	
09 Aug 2011
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
14/304,313
    	
 
    	
13 Jun 2014
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
11/133,190
    	
 
    	
18 Nov 2003
    	
 
    	
 
    	
 
    	
20050277687
    	
 
    	
 
    	
 
    	
7786160
    	
 
    	
31 Aug 2010
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/834,641
    	
 
    	
18 Nov 2003
    	
 
    	
 
    	
 
    	
20100280017
    	
 
    	
 
    	
 
    	
8420691
    	
 
    	
16 Apr 2013
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/717,977
    	
 
    	
18 Nov 2003
    	
 
    	
 
    	
 
    	
20130109733
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
11/774,816
    	
 
    	
18 Nov 2003
    	
 
    	
 
    	
 
    	
20070249724
    	
 
    	
 
    	
 
    	
8003701
    	
 
    	
23 Aug 2011
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/834,655
    	
 
    	
18 Nov 2003
    	
 
    	
 
    	
 
    	
20100280129
    	
 
    	
 
    	
 
    	
8618177
    	
 
    	
31 Dec 2013
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/834,664
    	
 
    	
18 Nov 2003
    	
 
    	
 
    	
 
    	
20100280126
    	
 
    	
 
    	
 
    	
8404749
    	
 
    	
26 Mar 2013
    	
 
    
	
Europe
    	
 
    	
Grunenthal GmbH
    	
 
    	
PCT/EP03/12882
    	
 
    	
18 Nov 2003
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/667,110
    	
 
    	
21 Jun 2004
    	
 
    	
 
    	
 
    	
20130060065
    	
 
    	
 
    	
 
    	
8704002
    	
 
    	
22 Apr 2014
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
11/294,449
    	
 
    	
04 Jun 2004
    	
 
    	
 
    	
 
    	
20060194988
    	
 
    	
 
    	
 
    	
7417170
    	
 
    	
26 Aug 2008
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/972,253
    	
 
    	
14 Jun 2011
    	
 
    	
 
    	
 
    	
20130338399
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/160,050
    	
 
    	
14 Jun 2011
    	
 
    	
 
    	
 
    	
20110306793
    	
 
    	
 
    	
 
    	
8669399
    	
 
    	
11 Mar 2014
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/113,582
    	
 
    	
30 Oct 2006
    	
 
    	
 
    	
 
    	
20090043132
    	
 
    	
 
    	
 
    	
8791300
    	
 
    	
29 Jul 2014
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
11/915,653
    	
 
    	
29 May 2006
    	
 
    	
 
    	
 
    	
20080269524
    	
 
    	
 
    	
 
    	
7649114
    	
 
    	
19 Jan 2010
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
14/478797
    	
 
    	
05 Sep 2014
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/374,874
    	
 
    	
23 Jul 2007
    	
 
    	
 
    	
 
    	
20100099916
    	
 
    	
 
    	
 
    	
8877974
    	
 
    	
04 Nov 2014
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/754,528
    	
 
    	
27 Apr 2007
    	
 
    	
 
    	
 
    	
20130190333
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
11/741,420
    	
 
    	
27 Apr 2007
    	
 
    	
 
    	
 
    	
20070254960
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/374,910
    	
 
    	
23 Jul 2007
    	
 
    	
 
    	
 
    	
20090326271
    	
 
    	
 
    	
 
    	
8263809
    	
 
    	
11 Sep 2012
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/106,695
    	
 
    	
21 Apr 2008
    	
 
    	
 
    	
 
    	
20090012180
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/329,111
    	
 
    	
05 Dec 2008
    	
 
    	
 
    	
 
    	
20090149534
    	
 
    	
 
    	
 
    	
8134032
    	
 
    	
13 Mar 2012
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/768,232
    	
 
    	
27 Apr 2010
    	
 
    	
 
    	
 
    	
20100280128
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/438,410
    	
 
    	
03 Apr 2012
    	
 
    	
 
    	
 
    	
20120309840
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/188,689
    	
 
    	
22 Jul 2011
    	
 
    	
 
    	
 
    	
20120022117
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/410,768
    	
 
    	
02 Mar 2012
    	
 
    	
 
    	
 
    	
20130022670
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/410,945
    	
 
    	
02 Mar 2012
    	
 
    	
 
    	
 
    	
20120225951
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/410,837
    	
 
    	
02 Mar 2012
    	
 
    	
 
    	
 
    	
20120225950
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/438,469
    	
 
    	
03 Apr 2012
    	
 
    	
 
    	
 
    	
20120309841
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
61/671,975
    	
 
    	
16 Jul 2012
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
61/673,948
    	
 
    	
20 Jul 2012
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
10/718,112
    	
 
    	
20 Nov 2003
    	
 
    	
 
    	
 
    	
20050031546
    	
 
    	
 
    	
 
    	
8114383
    	
 
    	
14 Feb 2012
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/346,257
    	
 
    	
20 Nov 2003
    	
 
    	
 
    	
 
    	
20120107250
    	
 
    	
 
    	
 
    	
8309060
    	
 
    	
13 Nov 2012
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
11/349,544
    	
 
    	
06 Feb 2006
    	
 
    	
 
    	
 
    	
20070183979
    	
 
    	
 
    	
 
    	
8075872
    	
 
    	
13 Dec 2011
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/270,505
    	
 
    	
06 Feb 2006
    	
 
    	
 
    	
 
    	
20120034171
    	
 
    	
 
    	
 
    	
8420056
    	
 
    	
16 Apr 2013
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
10/890,704
    	
 
    	
14 Jul 2004
    	
 
    	
 
    	
 
    	
20060002859
    	
 
    	
 
    	
 
    	
8114384
    	
 
    	
14 Feb 2012
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/358,415
    	
 
    	
23 Jan 2009
    	
 
    	
 
    	
 
    	
20090202634
    	
 
    	
 
    	
 
    	
8383152
    	
 
    	
26 Feb 2013
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
14/138,372
    	
 
    	
03 Aug 2006
    	
 
    	
 
    	
 
    	
20140170079
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
14/138,323
    	
 
    	
20 Nov 2003
    	
 
    	
 
    	
 
    	
20140105830
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
11/462,216
    	
 
    	
03 Aug 2006
    	
 
    	
 
    	
 
    	
20070048228
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
14/087,017
    	
 
    	
05 Aug 2004
    	
 
    	
 
    	
 
    	
20140080915
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
14/458,526
    	
 
    	
13 Aug 2014
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
Country
    	
 
    	
Assignee
    	
 
    	
Application No.
    	
 
    	
Filing Date
    	
 
    	
Status
    	
 
    	
Publication No.
    	
 
    	
Publication Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
11/471,438
    	
 
    	
23 Dec 2004
    	
 
    	
 
    	
 
    	
20070003616
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
14/174,876
    	
 
    	
14 Jul 2004
    	
 
    	
 
    	
 
    	
20140155489
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/897,746
    	
 
    	
14 Jul 2004
    	
 
    	
 
    	
 
    	
20130251643
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
14/508,262
    	
 
    	
07 Oct 2014
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
11/348,276
    	
 
    	
06 Feb 2006
    	
 
    	
 
    	
 
    	
20060188447
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
14/564,188
    	
 
    	
09 Dec 2014
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
14/261,625
    	
 
    	
25 Apr 2014
    	
 
    	
 
    	
 
    	
20140322323
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/840,439
    	
 
    	
20 Jul 2010
    	
 
    	
 
    	
 
    	
20110038930
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
12/916,988
    	
 
    	
08 May 2009
    	
 
    	
 
    	
 
    	
20110082214
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/018,629
    	
 
    	
01 Feb 2011
    	
 
    	
 
    	
 
    	
20110187017
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
13/962098
    	
 
    	
8 Aug 2013
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
US
    	
 
    	
Grunenthal GmbH
    	
 
    	
14/580578
    	
 
    	
23 Dec 2014
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

ANNEX F

 

TRADEMARKS AND TRADEMARK APPLICATIONS

 

	
MARK
    	
 
    	
COUNTRY
    	
 
    	
OWNER
    	
 
    	
APPLICATION
   #
    	
 
    	
FILE DATE
    	
 
    	
REGISTRATION
   #
    	
 
    	
REGISTRATION
   DATE
    	
 
    	
STATUS
    	
 
    
	
ACUFORM
    	
 
    	
CANADA
    	
 
    	
Depomed, Inc.
    	
 
    	
1307059
    	
 
    	
6/27/2006
    	
 
    	
TMA771374
    	
 
    	
7/6/2010
    	
 
    	
REGISTERED
    	
 
    
	
ACUFORM
    	
 
    	
EUROPEAN UNION (CTM)
    	
 
    	
Depomed, Inc.
    	
 
    	
5152517
    	
 
    	
6/21/2006
    	
 
    	
5152517
    	
 
    	
10/4/2007
    	
 
    	
REGISTERED
    	
 
    
	
ACUFORM
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
78781863
    	
 
    	
12/28/2005
    	
 
    	
3604419
    	
 
    	
4/7/2009
    	
 
    	
REGISTERED
    	
 
    
	
BREAKING THROUGH: VOICES OF BREAKTHROUGH PAIN IN CANCER   PATIENTS
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
85386630
    	
 
    	
8/2/2011
    	
 
    	
4335560
    	
 
    	
5/14/2013
    	
 
    	
REGISTERED
    	
 
    
	
CAMBIA
    	
 
    	
CANADA
    	
 
    	
Depomed, Inc.
    	
 
    	
1492818
    	
 
    	
8/18/2010
    	
 
    	
TMA806381
    	
 
    	
9/9/2011
    	
 
    	
REGISTERED
    	
 
    
	
CAMBIA
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
77441592
    	
 
    	
4/7/2008
    	
 
    	
3677383
    	
 
    	
9/1/2009
    	
 
    	
REGISTERED
    	
 
    
	
CAMBIA & Design


    	
 
    	
CANADA
    	
 
    	
Depomed, Inc.
    	
 
    	
1648121
    	
 
    	
10/21/2013
    	
 
    	
 
    	
 
    	
 
    	
 
    	
PUBLISHED
    	
 
    
	
CAMBIA & Design


    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
85907106
    	
 
    	
4/17/2013
    	
 
    	
4541984
    	
 
    	
6/3/2014
    	
 
    	
REGISTERED
    	
 
    
	
DEPOMED
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
74556760
    	
 
    	
8/3/1994
    	
 
    	
2112593
    	
 
    	
11/11/1997
    	
 
    	
REGISTERED
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
MARK
    	
 
    	
COUNTRY
    	
 
    	
OWNER
    	
 
    	
APPLICATION
   #
    	
 
    	
FILE DATE
    	
 
    	
REGISTRATION
   #
    	
 
    	
REGISTRATION
   DATE
    	
 
    	
STATUS
    	
 
    
	
DEPOMED & Design


    	
 
    	
CANADA
    	
 
    	
Depomed, Inc.
    	
 
    	
1307060
    	
 
    	
6/27/2006
    	
 
    	
TMA815153
    	
 
    	
1/9/2012
    	
 
    	
REGISTERED
    	
 
    
	
DEPOMED & Design


    	
 
    	
EUROPEAN UNION (CTM)
    	
 
    	
Depomed, Inc.
    	
 
    	
5152491
    	
 
    	
6/21/2006
    	
 
    	
5152491
    	
 
    	
6/21/2006
    	
 
    	
REGISTERED
    	
 
    
	
DEPOMED & Design


    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
78781903
    	
 
    	
12/28/2005
    	
 
    	
3865964
    	
 
    	
10/19/2010
    	
 
    	
REGISTERED
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
MARK
    	
 
    	
COUNTRY
    	
 
    	
OWNER
    	
 
    	
APPLICATION
   #
    	
 
    	
FILE DATE
    	
 
    	
REGISTRATION
   #
    	
 
    	
REGISTRATION
   DATE
    	
 
    	
STATUS
    	
 
    
	
DEPOMED & Star Design


    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
85114403
    	
 
    	
8/24/2010
    	
 
    	
4139790
    	
 
    	
5/8/2012
    	
 
    	
REGISTERED
    	
 
    
	
DEPOMED SIMPLE SCRIPT
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Unfiled
    	
 
    
	
G & Design


    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
86472401
    	
 
    	
12/5/2014
    	
 
    	
 
    	
 
    	
 
    	
 
    	
PENDING
    	
 
    
	
GRALISE
    	
 
    	
CANADA
    	
 
    	
Depomed, Inc.
    	
 
    	
1469350
    	
 
    	
2/11/2010
    	
 
    	
 
    	
 
    	
 
    	
 
    	
ALLOWED
    	
 
    
	
GRALISE
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
77934261
    	
 
    	
2/12/2010
    	
 
    	
4132334
    	
 
    	
4/24/2012
    	
 
    	
REGISTERED
    	
 
    
	
HEAR ME & Design


    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
86186380
    	
 
    	
2/6/2014
    	
 
    	
4605029
    	
 
    	
9/16/2014
    	
 
    	
REGISTERED
    	
 
    
	
LAZANDA
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
85196378
    	
 
    	
12/13/2010
    	
 
    	
4068538
    	
 
    	
12/6/2011
    	
 
    	
REGISTERED
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
MARK
    	
 
    	
COUNTRY
    	
 
    	
OWNER
    	
 
    	
APPLICATION
   #
    	
 
    	
FILE DATE
    	
 
    	
REGISTRATION
   #
    	
 
    	
REGISTRATION
   DATE
    	
 
    	
STATUS
    	
 
    
	
LAZANDA & Design


    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
85302528
    	
 
    	
4/22/2011
    	
 
    	
4104596
    	
 
    	
2/28/2012
    	
 
    	
REGISTERED
    	
 
    
	
Lazanda Logo


    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
85302550
    	
 
    	
4/22/2011
    	
 
    	
4104597
    	
 
    	
2/28/2012
    	
 
    	
REGISTERED
    	
 
    
	
NEURONETWORX
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
85907087
    	
 
    	
4/17/2013
    	
 
    	
 
    	
 
    	
 
    	
 
    	
ALLOWED
    	
 
    
	
PROQUIN
    	
 
    	
CANADA
    	
 
    	
Depomed, Inc.
    	
 
    	
1255613
    	
 
    	
4/27/2005
    	
 
    	
TMA679996
    	
 
    	
1/22/2007
    	
 
    	
DO NOT RENEW
    	
 
    
	
PROQUIN
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
78356939
    	
 
    	
1/23/2004
    	
 
    	
2968719
    	
 
    	
7/12/2005
    	
 
    	
DO NOT RENEW
    	
 
    
	
PROSORB
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
75544030
    	
 
    	
8/28/1998
    	
 
    	
2346573
    	
 
    	
5/2/2000
    	
 
    	
REGISTERED
    	
 
    
	
SERADA
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
77040022
    	
 
    	
11/8/2006
    	
 
    	
3795949
    	
 
    	
6/1/2010
    	
 
    	
DO NOT RENEW
    	
 
    
	
SIMPLESCRIPT
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Unfiled
    	
 
    
	
STAR DESIGN


    	
 
    	
CANADA
    	
 
    	
Depomed, Inc.
    	
 
    	
1583639
    	
 
    	
6/26/2012
    	
 
    	
 
    	
 
    	
 
    	
 
    	
PENDING
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 













 

	
MARK
    	
 
    	
COUNTRY
    	
 
    	
OWNER
    	
 
    	
APPLICATION
   #
    	
 
    	
FILE DATE
    	
 
    	
REGISTRATION
   #
    	
 
    	
REGISTRATION
   DATE
    	
 
    	
STATUS
    	
 
    
	
STAR DESIGN


    	
 
    	
EUROPEAN UNION (CTM)
    	
 
    	
Depomed, Inc.
    	
 
    	
5152566
    	
 
    	
6/21/2006
    	
 
    	
05152566
    	
 
    	
9/20/2007
    	
 
    	
REGISTERED
    	
 
    
	
Wave Design


    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
79087404
    	
 
    	
9/6/2010
    	
 
    	
3988050
    	
 
    	
7/5/2011
    	
 
    	
REGISTERED
    	
 
    
	
ZIPSOR
    	
 
    	
MEXICO
    	
 
    	
Xanodyne Pharmaceuticals, Inc.
    	
 
    	
1179843
    	
 
    	
5/20/2011
    	
 
    	
1244872
    	
 
    	
10/18/2011
    	
 
    	
REGISTERED
    	
 
    
	
ZIPSOR
    	
 
    	
PUERTO RICO
    	
 
    	
Xanodyne Pharmaceuticals, Inc.
    	
 
    	
76506
    	
 
    	
5/27/2011
    	
 
    	
1244872
    	
 
    	
 
    	
 
    	
REGISTERED
    	
 
    
	
ZIPSOR
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
77681532
    	
 
    	
3/2/2009
    	
 
    	
3732682
    	
 
    	
12/29/2009
    	
 
    	
REGISTERED
    	
 
    
	
ZIPSOR
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
77219449
    	
 
    	
6/29/2007
    	
 
    	
3725984
    	
 
    	
12/15/2009
    	
 
    	
REGISTERED
    	
 
    
	
NUCYNTA
    	
 
    	
UNITED STATES
    	
 
    	
Depomed, Inc.
    	
 
    	
77620713
    	
 
    	
4/21/2009
    	
 
    	
3732548
    	
 
    	
12/29/2009
    	
 
    	
REGISTERED 
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 












 

ANNEX G

 

DEPOSIT ACCOUNTS

 

 

	
Pledgor
    	
 
    	
Name of
   Depository
   Institution
    	
 
    	
Account
   Name
    	
 
    	
Account Number
    	
 
    	
Type/Purpose
    
	
Depomed, Inc.
    	
 
    	
Wells   Fargo Bank
    	
 
    	
N/A
    	
 
    	
[***]
    	
 
    	
Checking
    
	
Depomed, Inc.
    	
 
    	
Wells   Fargo Bank
    	
 
    	
N/A
    	
 
    	
[***]
    	
 
    	
Checking
    
	
Depomed, Inc.
    	
 
    	
Wells   Fargo Bank
    	
 
    	
N/A
    	
 
    	
[***]
    	
 
    	
Checking
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 











 

ANNEX H

 

SECURITIES ACCOUNTS

 

	
Pledgor
    	
 
    	
Name of
   Securities
   Intermediary
    	
 
    	
Account
   Name
    	
 
    	
Account Number
    	
 
    	
Type/Purpose
    
	
Depomed, Inc.
    	
 
    	
Oppenheimer
    	
 
    	
N/A
    	
 
    	
[***]
    	
 
    	
Investments
    
	
Depomed, Inc.
    	
 
    	
Wells   Fargo Capital
    	
 
    	
N/A
    	
 
    	
[***]
    	
 
    	
Investments
    
	
Depomed, Inc.
    	
 
    	
Morgan   Stanley Smith Barney
    	
 
    	
N/A
    	
 
    	
[***]
    	
 
    	
Investments
    


 

COMMODITY ACCOUNTS

 

[N/A]

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 











 

ANNEX I

 

COMMERCIAL TORT CLAIMS

 

Depomed is a party to the litigations described under the caption “Depomed v. Gralise® ANDA Filers” in the “Legal Proceedings” section of Depomed’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on February 2, 2015.

 

NJ                                  3:2012-cv-01358        DEPOMED, INC. v. ACTAVIS ELIZABETH LLC et al

 

Depomed is a party to the litigations described under the caption “Depomed v. Banner Pharmacaps” in the “Legal Proceedings” section of Depomed’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on February 2, 2015.

 

NJ                                  2:2013-cv-04542        DEPOMED, INC. v. BANNER PHARMACAPS INC. et al

1:2013-cv-00653

 

Depomed is a party to the litigations described under the caption “Depomed v. Purdue and Depomed v. Endo Pharmaceuticals—Patent Infringement Litigation and Related Inter Partes Review Procee” in the “Legal Proceedings” section of Depomed’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on February 2, 2015.

 

NJ                                  3:2013-cv-02467        DEPOMED, INC. v. ENDO PHARMACEUTICALS INC.

3:2013-cv-00571        DEPOMED, INC. v. PURDUE PHARMA, L.P. et al

 

Acquired Commercial Tort Claims from Janssen Pharmaceutics, Inc.:

 

1. Janssen Pharmaceuticals, Inc. and Grunenthal GmbH v. Actavis Elizabeth LLC and Alkem Laboratories Ltd, 2:13-cv-04507 (D.N.J) filed on July 25, 2013; in discovery).

 

2. Janssen Pharmaceuticals, Inc. and Grunenthal GmbH v. Roxane Laboratories, Inc., 2:13-cv-06929 (D.N.J) (filed on November 14, 2013; in discovery).

 

3. Janssen Pharmaceuticals, Inc. and Grunenthal GmbH v. Alkem Laboratories Ltd., 2:13-cv-0783 (D.N.J) (filed on December 23, 2013; in discovery).

 

4. Janssen Pharmaceuticals, Inc. and Grunenthal GmbH v. Roxane Laboratories, Inc., 2:14-cv-03941 (D.N.J) (filed on June 19, 2014; in discovery).

 

5. Janssen Pharmaceuticals, Inc. and Grunenthal GmbH v. Watson Laboratories, Inc., 2:14-cv-04617(D.N.J) (filed on July 23, 2014; in discovery).

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 











 

EXHIBIT A

 

GRANT OF SECURITY INTEREST IN COPYRIGHTS

 

WHEREAS, [NAME OF PLEDGOR] (the “Pledgor”) is the owner of the copyright applications and registrations listed on Schedule A attached hereto (all such copyrights, registrations and applications, collectively, the “Copyrights”); and

 

WHEREAS, the Pledgor has entered into a Pledge and Security Agreement (as amended, modified, restated or supplemented from time to time, the “Security Agreement”), dated as of April 2, 2015, in which the Pledgor has agreed with Deerfield Private Design Fund III, L.P., as Collateral Agent (the “Collateral Agent”), with offices at 780 Third Avenue, 37th Floor, New York, New York 10017, to execute this Grant;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, as security for the payment and performance of the Secured Obligations (as defined in the Security Agreement), the Pledgor does hereby grant to the Collateral Agent a security interest in all of its right, title and interest in and to the Copyrights, and the use thereof, together with all proceeds and products thereof.  This Grant has been given in conjunction with the security interest granted to the Collateral Agent under the Security Agreement, and the provisions of this Grant are without prejudice to and in addition to the provisions of the Security Agreement, which are incorporated herein by this reference.

 

This Grant of Security Interest in Copyrights and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement shall be governed by, and construed in accordance with, the law of the State of New York.

 

	
 
    	
[NAME   OF PLEDGOR]
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 











 

Schedule A

 

COPYRIGHTS AND COPYRIGHT APPLICATIONS

 

	
Owner
    	
 
    	
Application or
   Registration No.
    	
 
    	
Country
    	
 
    	
Registration or
   Filing Date
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    


 

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

2











 

EXHIBIT B

 

GRANT OF SECURITY INTEREST
 IN PATENTS AND TRADEMARKS

 

WHEREAS, [NAME OF PLEDGOR] (the “Pledgor”) is the owner of the trademark applications and registrations listed on Schedule A attached hereto, (all such trademarks, registrations and applications, collectively, the “Trademarks”) and is the owner of the patents and patent applications listed on Schedule A attached hereto (all such patents, registrations and applications, collectively, the “Patents”); and

 

WHEREAS, the Pledgor has entered into a Pledge and Security Agreement (as amended, modified, restated or supplemented from time to time, the “Security Agreement”), dated as of April 2, 2015, in which the Pledgor has agreed with Deerfield Private Design Fund III, L.P., as Collateral Agent (the “Collateral Agent”), with offices at 780 Third Avenue, 37th Floor, New York, New York 10017, to execute this Grant;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, as security for the payment and performance of the Secured Obligations (as defined in the Security Agreement), the Pledgor does hereby grant to the Collateral Agent a security interest in all of its right, title and interest in and to the Trademarks and the Patents, and the use thereof, together with all proceeds and products thereof and the goodwill of the businesses symbolized by the Trademarks.  This Grant has been given in conjunction with the security interest granted to the Collateral Agent under the Security Agreement, and the provisions of this Grant are without prejudice to and in addition to the provisions of the Security Agreement, which are incorporated herein by this reference.

 

This Grant of Security Interest in Patents and Trademarks and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement shall be governed by, and construed in accordance with, the law of the State of New York.

 

	
 
    	
[NAME   OF PLEDGOR]
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 












 

Schedule A

 

TRADEMARKS AND TRADEMARK APPLICATIONS

 

	
Owner
    	
 
    	
Mark
    	
 
    	
Application or
   Registration No.
    	
 
    	
Country
    	
 
    	
Issue or
   Filing Date
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    


 

PATENTS AND PATENT APPLICATIONS

 

	
Owner
    	
 
    	
Application or
   Registration No.
    	
 
    	
Country
    	
 
    	
Inventor
    	
 
    	
Issue or
   Filing Date
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

2











 

EXHIBIT C

 

FORM OF
 PLEDGOR ACCESSION

 

THIS PLEDGOR ACCESSION (this “Accession”), dated as of                           , 20      , is executed and delivered by [NAME OF NEW PLEDGOR], a                              (the “New Pledgor”), in favor of Deerfield Private Design Fund III, L.P., in its capacity as Collateral Agent under the Note Purchase Agreement referred to below (in such capacity, the “Collateral Agent”), pursuant to the Security Agreement referred to below.

 

Reference is made to the Note Purchase Agreement, dated as of March 12, 2015, among Depomed, Inc. (the “Borrower”), the Purchasers party thereto and the Collateral Agent (as amended, modified, restated or supplemented from time to time, the “Note Purchase Agreement”).  In connection with and as a condition to the purchase of the Notes by the Purchasers under the Note Purchase Agreement, (i) Depo NF Sub, LLC,  a Subsidiary of the Borrower (the “Guarantor”), pursuant to a Guaranty Agreement, dated as of the date of the Note Purchase Agreement (as amended, modified, restated or supplemented from time to time, the “Guaranty Agreement”), has guaranteed the payment in full of the obligations of the Borrower under the Note Purchase Agreement and the other Credit Documents (as defined in the Note Purchase Agreement), and (ii) the Borrower and the Guarantor, pursuant to a Pledge and Security Agreement, dated as of the date of the Note Purchase Agreement (as amended, modified, restated or supplemented from time to time, the “Security Agreement”), have granted in favor of the Collateral Agent a security interest in and Lien upon the Collateral described therein as security for their obligations under the Note Purchase Agreement, the Guaranty Agreement and the other Credit Documents.  Capitalized terms used herein without definition shall have the meanings given to them in the Security Agreement.

 

The Borrower has agreed under the Note Purchase Agreement to cause certain of its future direct and indirect subsidiaries to become a party to the Guaranty Agreement as a guarantor thereunder and to the Security Agreement as a Pledgor thereunder.  The New Pledgor is a direct or indirect subsidiary of the Borrower and, as required by the Note Purchase Agreement, has become a guarantor under the Guaranty Agreement as of the date hereof.  The New Pledgor will obtain benefits as a result of the sale by the Borrower of the Notes to the Purchaser under the Note Purchase Agreement, which benefits are hereby acknowledged, and, accordingly, desire to execute and deliver this Accession.  Therefore, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and as further inducement to the Purchasers in connection with their purchase of the Notes from the Borrower under the Note Purchase Agreement, the New Pledgor hereby agrees as follows:

 

1.                                      The New Pledgor hereby joins in and agrees to be bound by each and all of the provisions of the Security Agreement as a Pledgor thereunder.  In furtherance (and without limitation) of the foregoing, pursuant to Section 2.1 of the Security Agreement, and as security for all of the Secured Obligations, the New Pledgor hereby pledges, assigns and delivers to the Collateral Agent, for the ratable benefit of the Secured Parties, and grants to the Collateral

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 











 

Agent, for the ratable benefit of the Secured Parties, a Lien upon and security interest in, all of its right, title and interest in and to the Collateral as set forth in Section 2.1 of the Security Agreement, all on the terms and subject to the conditions set forth in the Security Agreement.

 

2.                                      The New Pledgor hereby represents and warrants that (i) Schedule 1 hereto sets forth all information required to be listed on Annexes A, B, C, D, E, F, G, H and I to the Security Agreement in order to make each representation and warranty contained in Sections 3.1 and 3.2 of the Security Agreement true and correct with respect to the New Pledgor as of the date hereof and after giving effect to this Accession and (ii) after giving effect to this Accession and to the incorporation into such Annexes, as applicable, of the information set forth in Schedule 1, each representation and warranty contained in Article III of the Security Agreement is true and correct with respect to the New Pledgor as of the date hereof, as if such representations and warranties were set forth at length herein.

 

3.                                      This Accession shall be a Credit Document (within the meaning of such term under the Note Purchase Agreement), shall be binding upon and enforceable against the New Pledgor and its successors and assigns, and shall inure to the benefit of and be enforceable by each Secured Party and its successors and assigns.  This Accession and its attachments are hereby incorporated into the Security Agreement and made a part thereof.

 

This Accession and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement shall be governed by, and construed in accordance with, the law of the State of New York.

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

2











 

IN WITNESS WHEREOF, the New Pledgor has caused this Accession to be executed under seal by its duly authorized officer as of the date first above written.

 

 

	
 
    	
[NAME   OF NEW PLEDGOR]
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

3











 

Schedule 1

 

Information to be added to Annex A of the Security Agreement:

 

FILING LOCATIONS

 

	
Name of Pledgor
    	
 
    	
Filing Location
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    


 

Information to be added to Annex B of the Security Agreement:

 

JURISDICTION OF ORGANIZATION, CERTAIN LOCATIONS

 

[Name of Pledgor:]

 

Jurisdiction of Incorporation/Organization:

 

Federal Tax ID no.:

 

Organizational ID no.:

 

Chief Executive Office Address:

 

Locations of Records Related to Collateral:

 

Locations of Equipment or Inventory:

 

Other places of business:

 

Trade/fictitious or prior corporate names
 (last five years):

 

Names used in tax filings (last five years):

 

Information to be added to [Annexes C/D/E/F/G/H/I] of the Security Agreement:

 

[Complete as applicable]

 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 

4











 

EXHIBIT D

 

PLEDGE AMENDMENT

 

THIS PLEDGE AMENDMENT, dated as of                               , 20      , is delivered by [NAME OF PLEDGOR] (the “Pledgor”) pursuant to Section 5.1 of the Security Agreement referred to below.  The Pledgor hereby agrees that this Pledge Amendment may be attached to the Pledge and Security Agreement, dated as of April 2, 2015, made by the Pledgor and certain other pledgors named therein in favor of Deerfield Private Design Fund III, L.P., as Collateral Agent (as amended, modified, restated or supplemented from time to time, the “Security Agreement,” capitalized terms defined therein being used herein as therein defined), and that the Pledged Interests listed on Schedule 1 to this Pledge Amendment shall be deemed to be part of the Pledged Interests within the meaning of the Security Agreement and shall become part of the Collateral and shall secure all of the Secured Obligations as provided in the Security Agreement.  This Pledge Amendment and its attachments are hereby incorporated into the Security Agreement and made a part thereof.

 

 

	
 
    	
[NAME   OF PLEDGOR]
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.

 











 

Schedule 1

 

PLEDGED INTERESTS

 

	
Name of Issuer
    	
 
    	
Type of
   Interests
    	
 
    	
Certificate
   Number
    	
 
    	
No. of shares
   (if applicable)
    	
 
    	
Percentage of
   Outstanding Interests
   in Issuer
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    


 

Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.